Disease on EC 3.4.11.22 - aminopeptidase I

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
Association of the R67X and W303X non-sense polymorphisms in the protein Z-dependent protease inhibitor gene with idiopathic recurrent miscarriage.
Increase in the plasma levels of protein Z-dependent protease inhibitor in normal pregnancies but not in non-pregnant patients with unexplained recurrent miscarriage.
Abortion, Spontaneous
ERAP, KIR and HLA-C gene interaction in susceptibility to recurrent spontaneous abortion in the Polish population.
Abscess
Escherichia coli hemoglobin protease autotransporter contributes to synergistic abscess formation and heme-dependent growth of Bacteroides fragilis.
Acantholysis
Cantharide acantholysis: endogenous protease activation leading to desmosomal plaque dissolution.
Effects of steroid, retinoid, and protease inhibitors on the formation of acantholysis induced in organ culture of skins from patients with benign familial chronic pemphigus.
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis.
Acanthosis Nigricans
Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors.
Achlorhydria
Observations on the etiologic relationship of achylia gastrica to pernicious anemia. XII. Failure of thymus aminopolypeptidase to act as intrinsic factor.
Acidosis, Lactic
Highly active antiretroviral therapy (HAART)-associated lactic acidosis: in vitro effects of combination of nucleoside analogues and protease inhibitors on mitochondrial function and lactic acid production.
Acne Vulgaris
Lipase, protease, and biofilm as the major virulence factors in staphylococci isolated from acne lesions.
Acquired Immunodeficiency Syndrome
A 'second life' agenda. Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome.
Cystoid macular edema in a patient with acquired immunodeficiency syndrome and past ocular history of cytomegalovirus retinitis after initiation of protease inhibitors.
Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996.
Lipemia retinalis in acquired immunodeficiency syndrome treated with protease inhibitors.
[Granular lymphocyte-proliferative disorder following initiation of protease inhibitor therapy in a patient with acquired immunodeficiency syndrome]
[Impact of anti-retroviral treatment with protease inhibitors on the evolution of cytomegalovirus retinitis in the patient carrying acquired immunodeficiency syndrome]
Acute Coronary Syndrome
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial.
[Acute coronary syndromes in patients treated with HIV protease inhibitors]
Acute Generalized Exanthematous Pustulosis
Acute generalized exanthematous pustulosis: a cutaneous adverse effect due to prophylactic antiviral therapy with protease inhibitor.
Life-threatening acute generalized exanthematous pustulosis induced by two different protease inhibitors in an HIV-1-infected patient.
Acute Kidney Injury
Lysosomal protease cathepsin D; a new driver of apoptosis during acute kidney injury.
[Pathophysiological mechanism of ischemic acute renal failure: protective effect of coenzyme Q10, Ca channel blocker, superoxide dismutase and protease inhibitor against ischemic acute renal failure]
Acute Lung Injury
Lard-based high-fat diet increases secretory leukocyte protease inhibitor expression and attenuates the inflammatory response of acute lung injury in endotoxemic rats.
Neutrophil proteinases in hydrochloric acid- and endotoxin-induced acute lung injury: evaluation of interstitial protease activity by in situ zymography.
Protease mechanisms in the pathogenesis of acute lung injury.
Role of protease activated receptor 2 in experimental acute lung injury and lung fibrosis.
Tissue factor-dependent coagulation protease signaling in acute lung injury.
[Experimental study on effect and mechanism of soybean protease inhibitor on endotoxin-induced acute lung injury]
[Inhibitory effects of protease inhibitor on endotoxin-induced acute lung injury in rats]
[Protective effect of a protease inhibitor on acute lung injury after hepatic ischemia/reperfusion in the rat]
Adenocarcinoma
Effects of media conditioned by a non-metastasizing human salivary gland adenocarcinoma cell clone and metastasizing clones from salivary gland and various other tissues on the proliferation, migration and protease production of bovine aortic endothelial cells in vitro.
Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors.
Pea (Pisum sativum L.) protease inhibitors from the Bowman-Birk class influence the growth of human colorectal adenocarcinoma HT29 cells in vitro.
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma.
Re: Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma.
Significance of effector protease receptor-1 expression and its relationship with proliferation and apoptotic index in patients with primary advanced gastric adenocarcinoma.
Soybean Bowman-Birk Protease Inhibitor (BBI): Identification of the Mechanisms of BBI Suppressive Effect on Growth of Two Adenocarcinoma Cell Lines: AGS and HT29.
Adenocarcinoma of Lung
Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma.
Ubiquitin-specific protease 4 controls metastatic potential through ?-catenin stabilization in brain metastatic lung adenocarcinoma.
Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma.
Adenoma
The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease.
Urinary protease inhibitor Serpin B3 is higher in women and is further increased in female patients affected by aldosterone producing adenoma.
Adenoviridae Infections
Inhibition of adenovirus infection with protease inhibitors.
Adrenoleukodystrophy
Protease inhibitors suppress the degradation of mutant adrenoleukodystrophy proteins but do not correct impairment of very long chain fatty acid metabolism in adrenoleukodystrophy fibroblasts.
African Swine Fever
African swine fever virus protease, a new viral member of the SUMO-1-specific protease family.
Polyprotein processing protease of African swine fever virus: purification and biochemical characterization.
Aggressive Periodontitis
Concentrations of serum protease inhibitors and immunoglobulins in juvenile periodontitis.
AIDS Dementia Complex
Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy.
Airway Obstruction
Ageing and smoking contribute to plasma surfactant proteins and protease imbalance with correlations to airway obstruction.
alpha 1-Antitrypsin Deficiency
[Mucous membrane specific protease inhibitors in bronchial mucus in severe chronic obstructive bronchitis and in alpha 1-antitrypsin deficiency syndrome]
Alveolitis, Extrinsic Allergic
Intracellular protease changes in acute experimental hypersensitivity pneumonitis.
Alzheimer Disease
A calcium-activated protease from Alzheimer's disease brain cleaves at the N-terminus of the amyloid beta-protein.
A protease activity associated with acetylcholinesterase releases the membrane-bound form of the amyloid protein precursor of Alzheimer's disease.
Aging and Alzheimer's disease: protease inhibitors in cerebrospinal fluid.
Alzheimer's disease. Enter a protease inhibitor.
Amyloid beta protein precursor with Kunitz-type protease inhibitor domains (APPI) in cerebrospinal fluid and APPI mRNAs in cultured skin fibroblasts of patients with Alzheimer's disease.
APP with Kunitz type protease inhibitor domain (KPI) correlates with neuritic plaque density but not with cortical synaptophysin immunoreactivity in Alzheimer's disease and non-demented aged subjects: a multifactorial analysis.
Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease.
BACE1 SUMOylation increases its stability and escalates the protease activity in Alzheimer's disease.
Ca(2+)-dependent 68-kilodalton protease in familial Alzheimer's disease cells cleaves the N-terminus of beta-amyloid.
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer's disease.
Decreases in protease nexins in Alzheimer's disease brain.
Enzyme specificity of proteinase inhibitor region in amyloid precursor protein of Alzheimer's disease: different properties compared with protease nexin I.
Functions of the Alzheimer's Disease Protease BACE1 at the Synapse in the Central Nervous System.
Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
Identification of human presequence protease (hPreP) agonists for the treatment of Alzheimer's disease.
Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.
Kunitz protease inhibitor-containing amyloid beta protein precursor immunoreactivity in Alzheimer's disease.
Lysosomal protease inhibitors induce meganeurites and tangle-like structures in entorhinohippocampal regions vulnerable to Alzheimer's disease.
Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.
Mitochondria and Alzheimer's disease: amyloid-beta peptide uptake and degradation by the presequence protease, hPreP.
Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament.
Molecular studies define the primary structure of alpha1-antichymotrypsin (ACT) protease inhibitor in Alzheimer's disease brains. Comparison of act in hippocampus and liver.
Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity.
Potential roles of protease inhibitors in Alzheimer's disease.
Predicted three-dimensional structure of the protease inhibitor domain of the Alzheimer's disease beta-amyloid precursor.
Prostaglandin E2 induced polymerization of human alpha-1-antichymotrypsin and suppressed its protease inhibitory activity: implications for Alzheimer's disease.
Protease inhibition causes some manifestations of aging and Alzheimer's disease in rodent and primate brain.
Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease.
Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease.
Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease.
Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.
Protease nexin I immunostaining in Alzheimer's disease.
Protease nexin-1, a potent thrombin inhibitor, is reduced around cerebral blood vessels in Alzheimer's disease.
Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease.
Proteases and Protease Inhibitors in Alzheimer's Disease Pathogenesis. Proceedings of a conference. Bethesda, Maryland, December 16-18, 1991.
Purification of a trypsin-type protease from human umbilical vein endothelial cells which is highly sensitive to the Kunitz inhibitor domain peptide of Alzheimer's disease amyloid protein precursor.
Relative increase in Alzheimer's disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain.
Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
Structure prediction of protease inhibitor region in amyloid precursor protein of Alzheimer's disease.
The amyloid beta-protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domain-sensitive trypsin-like serine protease in cultures of chick sympathetic neurons.
The Effect of HIV Protease Inhibitors on Amyloid-? Peptide Degradation and Synthesis in Human Cells and Alzheimer's Disease Animal Model.
The involvement of proteases, protease inhibitors, and an acute phase response in Alzheimer's disease.
The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond.
The protease inhibitor, alpha 1-antichymotrypsin, is a component of the brain amyloid deposits in normal aging and Alzheimer's disease.
Tissue-specific expression of three types of beta-protein precursor mRNA: enhancement of protease inhibitor-harboring types in Alzheimer's disease brain.
Understanding BACE1: essential protease for amyloid-beta production in Alzheimer's disease.
[Therapeutic strategy by manipulating some protease activities for Alzheimer's disease]
aminopeptidase i deficiency
Aminopeptidase yscII of yeast. Isolation of mutants and their biochemical and genetic analysis.
In the absence of aminopeptidase ERAAP, MHC class I molecules present many unstable and highly immunogenic peptides.
Isolation and characterization of Schizosaccharomyces pombe mutants lacking aminopeptidase activity.
Sculpting MHC class II-restricted self and non-self peptidome by the class I Ag-processing machinery and its impact on Th-cell responses.
The role of endoplasmic reticulum-associated aminopeptidase 1 in immunity to infection and in cross-presentation.
Amyloidosis
Alpha 2-macroglobulin protects some of the protein constituents of dialysis-associated amyloidosis from protease degradation.
Cathepsin protease activity modulates amyloid load in extracerebral amyloidosis.
Amyotrophic Lateral Sclerosis
Cytoplasmic, lysosomal and matrix protease activities in spinal cord tissue from amyotrophic lateral sclerosis (ALS) and control patients.
Occurrence of reduced alpha 2-macroglobulin and lowered protease inhibiting capacity in plasma of amyotrophic lateral sclerosis patients.
Studies of protease inhibitors in the sera of patients with amyotrophic lateral sclerosis.
Anaphylaxis
Mechanism of anaphylaxis in the rabbit; further evidence against plasma protease mechanism.
Studies on tissue protease. V. Protease activity of tissues under anaphylactic shock state.
Androgen-Insensitivity Syndrome
Induction of androgen-dependent protease and serous-like granules by tri-iodothyronine in the submandibular gland of mice with testicular feminization.
Anemia
Combination antiretroviral therapy including a protease inhibitor eliminated the transfusion requirements of HIV-infected individuals with anemia of chronic disease.
delta-Aminolevulinic acid synthetase in erythroblasts of patients with pyridoxine-responsive anemia. Hypercatabolism caused by the increased susceptibility to the controlling protease.
Dual Mutation Events in the Haemagglutinin-Esterase and Fusion Protein from an Infectious Salmon Anaemia Virus HPR0 Genotype Promote Viral Fusion and Activation by an Ubiquitous Host Protease.
Expression of functional protease and subviral particles by vaccinia virus containing equine infectious anaemia virus gag and 5' pol genes.
Expression of the protease gene of equine infectious anemia virus in Escherichia coli: formation of the mature processed enzyme and specific cleavage of the gag precursor.
Increased plasma glycosidase and protease activity in uraemia: possible role in the aetiology of the anaemia of chronic renal failure.
Management of anemia in patients receiving protease inhibitors.
Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients.
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
Anemia, Iron-Deficiency
Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
Anemia, Pernicious
Observations on the etiologic relationship of achylia gastrica to pernicious anemia. XII. Failure of thymus aminopolypeptidase to act as intrinsic factor.
Anemia, Sideroblastic
Ferritin and sideroblastic anaemias: inhibition of protein synthesis by protease contaminants in commercial preparations of ferritin.
Aneurysm
Smad2-Dependent Protease Nexin-1 Overexpression Differentiates Chronic Aneurysms From Acute Dissections of Human Ascending Aorta.
Angioedemas, Hereditary
Protease inhibitors in the treatment of hereditary angioedema.
Studies of four Japanese families with hereditary angioneurotic edema: simultaneous activation of plasma protease systems and exogenous triggering stimuli.
Anthrax
Activation of plasminogen activator inhibitor implicates protease InhA in the acute-phase response to Bacillus anthracis infection.
Feeding Anthrax: The Crystal Structure of Bacillus anthracis InhA Protease.
Fine structure analysis of the amino acid sequence recognized by the eukaryotic cell protease that activates anthrax toxin.
Low molecular weight inhibitors of the protease anthrax lethal factor.
Purification and Biophysical Characterization of the Core Protease Domain of Anthrax Lethal Factor.
Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease.
Small-Molecule Inhibitors of Lethal Factor Protease Activity Protect against Anthrax Infection.
Ultrasensitive detection of protease activity of anthrax and botulinum toxins by a new PCR-based assay.
Aortic Aneurysm
Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms.
Aortic Aneurysm, Abdominal
Altered aortic protease and antiprotease activity in patients with ruptured abdominal aortic aneurysms.
Difference in matrix-degrading protease expression and activity between thrombus-free and thrombus-covered wall of abdominal aortic aneurysm.
Protease activity in the multi-layered intra-luminal thrombus of abdominal aortic aneurysms.
Reduced protease inhibitory capacity in patients with abdominal aortic aneurysms is reversed with surgical repair.
Aortitis
Experimental aortitis. Aortic lesions induced by a serine protease.
Arteriosclerosis
Protease therapy alleviates allograft arteriosclerosis in rats.
Arthralgia
Arthralgias and cryoglobulinemia during protease inhibitor therapy in a patient infected with human immunodeficiency virus and hepatitis C virus.
Arthritis
Effect of Cervus korean TEMMINCK var. mantchuricus Swinhoe on protease activities, antioxidant and free radical damages in rheumatis arthritis rats.
ERAP1 rs30187 single nucleotide polymorphism does not confer disease susceptibility in North Indian children with enthesitis-related arthritis.
In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response.
Perturbation of protease inhibitors and substrates in inflammatory arthritis.
Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis.
Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis.
Suppression of streptococcal cell wall-induced arthritis by a potent protease inhibitor, bis(5-amidino-2-benzimidazolyl)methane.
[Arthritis and ADAM family protease]
[Modification of the adjuvans arthritis by carrageenin, compound 48/80, histamine- and serotonin antagonists, non-steroid antiphlogistics as well as protease inhibitors and their possible relations to inflammation mediators]
[Radioisotope evaluation with Tc 99m of the anti-inflammatory effect of a protease inhibitor in arthritis due to immune complexes and micro-crystals]
Arthritis, Experimental
An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats.
Effects of FUT-175, a novel synthetic protease inhibitor, on the development of adjuvant arthritis in rats and some biological reactions dependent on complement activation.
LPS increases the incidence of collagen-induced arthritis in mice through induction of protease HTRA1 expression.
[Changes of mucopolysaccharase, protease and collagenolytic activities in rats with adjuvant arthritis and the effects of various anti-inflammatory drugs]
Arthritis, Infectious
Impact of staphylococcal protease expression on the outcome of infectious arthritis.
Arthritis, Juvenile
Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis.
Arthritis, Psoriatic
ERAP1 and ERAP2 Gene Variations Influence the Risk of Psoriatic Arthritis in Romanian Population.
Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis.
Genetics of spondyloarthritis--beyond the MHC.
Arthritis, Rheumatoid
Association of HLA-DR4, protease inhibitor phenotypes and keratoconjunctivitis sicca with pulmonary abnormalities in rheumatoid arthritis.
Characteristics of the protease activity in synovial fluid from patients with rheumatoid arthritis and osteoarthritis.
Distinct expression of mast cell tryptase and protease activated receptor-2 in synovia of rheumatoid arthritis and osteoarthritis.
Effects of bee venom on protease activities and free radical damages in synovial fluid from type II collagen-induced rheumatoid arthritis rats.
ERAP1 association with ankylosing spondylitis is attributable to common genotypes rather than rare haplotype combinations.
Human gelatinase B, a marker enzyme in rheumatoid arthritis, is inhibited by D-penicillamine: anti-rheumatic activity by protease inhibition.
Large multifunctional protease 2 genes in rheumatoid arthritis.
Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study.
Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis.
The effect of protease inhibitors on the polyclonal B cell activator from the serum of patients with rheumatoid arthritis.
The inhibitory effect of IFN-? on protease HTRA1 expression in rheumatoid arthritis.
[Information value of indices of the protease inhibitor system in diagnosing the early stage of rheumatoid arthritis]
[Protease inhibitors in the complex treatment of rheumatoid arthritis]
[Study of protease inhibitory system (Pi) in rheumatoid arthritis]
[The status of various indicators of the protease inhibitor system in blood and synovial fluid in rheumatoid arthritis]
Arthus Reaction
Protease inhibitors reduce the reverse passive Arthus reaction.
[On the increase in the serum protease activity (dipeptidase and tripeptidase) in the Arthus phenomenon.]
Aspergillosis
Functional protease profiling for laboratory based diagnosis of invasive aspergillosis.
Secretion of a fungal protease represents a complement evasion mechanism in cerebral aspergillosis.
Asthma
A fungal protease allergen provokes airway hyper-responsiveness in asthma.
Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma.
Allergic reactions, including asthma, to the pineapple protease bromelain following occupational exposure.
Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma.
Preliminary study of use of buccal protease therapy in bronchial asthma.
Protease activated receptor-2 mediated dual oxidase-2 upregulation is involved in enhanced airway reactivity and inflammation in a mouse model of allergic asthma.
Protease inhibitor variants in children and young adults with chronic asthma.
Protease inhibitors in respiratory disease: focus on asthma and chronic obstructive pulmonary disease.
Secretory leukocyte protease inhibitor plays an important role in the regulation of allergic asthma in mice.
Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma.
The Effect of Liposome Encapsulation on the Pharmacokinetics of Recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) Therapy after Local Delivery to a Guinea Pig Asthma Model.
The influence of protease inhibitor on the progress of bronchial asthma.
Use of buccal protease therapy in chronic bronchial asthma.
[Effectiveness of the calcium antagonist nifedipine and the protease inhibitor with plasmin inactivating effect para-aminomethylbenzoic acid on stress-induced bronchial asthma]
[State of protease inhibitor system in patients with occupational bronchial asthma caused by nonferrous metal aerosols]
Asthma, Occupational
Occupational Asthma to Detergent Protease Associated With a Late-Phase Neutrophilic Cutaneous Response.
Astrocytoma
General protease and collagenase (IV) activity in C6 astrocytoma cells, C6 spheroids and implanted C6 spheroids.
Ataxia
Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease.
Transgenic rescue of ataxia mice with neuronal-specific expression of ubiquitin-specific protease 14.
Atherosclerosis
Acipimox, an Inhibitor of Lipolysis, Attenuates Atherogenesis in LDLR-Null Mice Treated With HIV Protease Inhibitor Ritonavir.
Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors.
Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.
Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors.
Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
HIV positivity, protease inhibitor exposure, and subclinical atherosclerosis: A systematic review and meta-analysis of observational studies.
HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease.
HIV protease inhibitors and atherosclerosis.
HIV protease inhibitors-induced atherosclerosis: prevention by alpha-tocopherol.
Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors.
Lipid lowering and imaging protease activation in atherosclerosis.
Loss of protease activity of ADAM15 abolishes protective effects on plaque progression in atherosclerosis.
Metalloproteinase-9 contributes to endothelial dysfunction in atherosclerosis via protease activated receptor-1.
Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C.
Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy.
Protease imaging of human atheromata captures molecular information of atherosclerosis, complementing anatomic imaging.
Secretory leukocyte protease inhibitor promising protective roles in obesity-associated atherosclerosis.
USP20 (Ubiquitin-Specific Protease 20) Inhibits TNF (Tumor Necrosis Factor)-Triggered Smooth Muscle Cell Inflammation and Attenuates Atherosclerosis.
Atrial Fibrillation
Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation.
Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation.
Autoimmune Diseases
Autoimmune Disease-Associated Variants of Extracellular Endoplasmic Reticulum Aminopeptidase 1 Induce Altered Innate Immune Responses by Human Immune Cells.
Autoimmune risk variants in ERAP2 are associated with gene-expression levels in thymus.
Coding single nucleotide polymorphisms of endoplasmic reticulum aminopeptidase 1 can affect antigenic peptide generation in vitro by influencing basic enzymatic properties of the enzyme.
Differences in SpeB protease activity among group A streptococci associated with superficial, invasive, and autoimmune disease.
Endoplasmic reticulum aminopeptidase 1 function and its pathogenic role in regulating innate and adaptive immunity in cancer and major histocompatibility complex class I-associated autoimmune diseases.
Endoplasmic reticulum aminopeptidase-1 functions regulate key aspects of the innate immune response.
ERAP1 and HLA-C interaction in inflammatory bowel disease in the Spanish population.
ERAP1 functions override the intrinsic selection of specific antigens as immunodominant peptides, thereby altering the potency of antigen-specific cytolytic and effector memory T-cell responses.
Immune surveillance for ERAAP dysfunction.
Influence of ERAP1 and ERAP2 gene polymorphisms on disease susceptibility in different populations.
Mice expressing human ERAP1 variants associated with ankylosing spondylitis have altered T-cell repertoires and NK cell functions, as well as increased in utero and perinatal mortality.
Molecular pathways for antigenic peptide generation by ER aminopeptidase 1.
Naturally occurring ERAP1 haplotypes encode functionally distinct alleles with fine substrate specificity.
Role of serine proteases in inflammation: Bowman-Birk protease inhibitor (BBI) as a potential therapy for autoimmune diseases.
The gene expression of two endoplasmic reticulum aminopeptidase 1 isoforms is regulated by distinct posttranscriptional mechanisms.
The putative role of endoplasmic reticulum aminopeptidases in autoimmunity: Insights from genomic-wide association studies.
Avian Leukosis
Reverse transcriptase and protease activities of avian leukosis virus Gag-Pol fusion proteins expressed in insect cells.
Azoospermia
The value of epididymal protease inhibitor in differential diagnosis between obstructive azoospermia and non-obstructive azoospermia.
Babesiosis
In Vitro Mode of Action and Anti-thrombotic Activity of Boophilin, a Multifunctional Kunitz Protease Inhibitor from the Midgut of a Tick Vector of Babesiosis, Rhipicephalus microplus.
Bacteremia
A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia.
Serum antibody concentrations of cytotoxin, exotoxin, A, lipopolysaccharide, protease, and elastase and survival of patients with Pseudomonas aeruginosa bacteremia.
Bacterial Infections
A common single nucleotide polymorphism in endoplasmic reticulum aminopeptidase 2 induces a specificity switch that leads to altered antigen processing.
Bifunctional Probes of Cathepsin Protease Activity and pH Reveal Alterations in Endolysosomal pHduring Bacterial Infection.
Clip domain prophenoloxidase activating protease is required for Ostrinia furnacalis Guene to defend against bacterial infection.
Protease activity sensors noninvasively classify bacterial infections and antibiotic responses.
Biliary Atresia
Association of X-prolyl aminopeptidase 1 rs17095355 polymorphism with biliary atresia in Thai children.
Blister
[Determination of leucine-aminopeptidase in the serum and blister fluid of some patients with skin diseases]
[Leucine-aminopeptidase activity in blood serum & blister content. I. Studies on persons with a normal skin.]
Bloom Syndrome
Protease inhibitors reduce the frequency of spontaneous chromosome abnormalities in cells from patients with Bloom syndrome.
Bone Cysts
TRE17/ubiquitin-specific protease 6 (USP6) oncogene translocated in aneurysmal bone cyst blocks osteoblastic maturation via an autocrine mechanism involving bone morphogenetic protein dysregulation.
Bone Resorption
V-ATPase subunit ATP6AP1 (Ac45) regulates osteoclast differentiation, extracellular acidification, lysosomal trafficking, and protease exocytosis in osteoclast-mediated bone resorption.
[Effects of protease inhibitors and protein synthesis inhibitors on cartilage tissue-dependent bone resorption]
Boutonneuse Fever
Rickettsia conorii infection stimulates the expression of ISG15 and ISG15 protease UBP43 in human microvascular endothelial cells.
Brain Edema
Effects of focal mild hypothermia on thrombin-induced brain edema formation and the expression of protease activated receptor-1, matrix metalloproteinase-9 and aquaporin 4 in rats.
Protease activated receptor-1 and brain edema formation in glioma models.
The expression and the role of protease nexin-1 on brain edema after intracerebral hemorrhage.
[Effect of agents increasing the resistance of the vascular wall as well as of trasylol (a protease inhibitor) on experimental brain edema]
Brain Injuries
Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.
Designer Adiponectin Receptor Agonist Stabilizes Metabolic Function and Prevents Brain Injury Caused by HIV Protease Inhibitors.
Effects of hypothermia on neonatal hypoxic-ischemic brain injury in the rat: phosphorylation of Akt, activation of caspase-3-like protease.
Neuroprotection against hypoxic-ischemic brain injury by inhibiting the apoptotic protease activating factor-1 pathway.
Regulation of neurons and astrocytes by thrombin and protease nexin-1. Relationship to brain injury.
Brain Ischemia
Endogenous Protease Nexin-1 Protects against Cerebral Ischemia.
Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors.
Microglial activation and matrix protease generation during focal cerebral ischemia.
Protease inhibitors for delayed cerebral ischemia after subarachnoid haemorrhage?
Brain Neoplasms
A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.
Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours.
Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
Breast Neoplasms
A novel matrix-degrading protease in hormone-dependent breast cancer.
A proteolytic activity in a human breast cancer cell line which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor.
Apoptosis and lysosome membrane permeabilization induction on breast cancer cells by an anticarcinogenic Bowman-Birk protease inhibitor from Vigna unguiculata seeds.
Breast carcinoma associated protein - a novel binding partner of Mason-Pfizer monkey virus protease.
Caspase-3 inhibits the growth of breast cancer cells independent of protease activity.
Cathepsin D: a protease involved in breast cancer metastasis.
Cathepsin G, a neutrophil protease, induces compact cell-cell adhesion in MCF-7 human breast cancer cells.
Cathepsin-D, a key protease in breast cancer, is up-regulated in obese mouse and human adipose tissue, and controls adipogenesis.
Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization.
Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype.
Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells.
Differential Regulation of Insulin-Like Growth Factor-Binding Protein-3 Protease Activity in MCF-7 Breast Cancer Cells by Estrogen and Transforming Growth Factor-?1.
Differential regulation of insulin-like growth factor-binding protein-3 protease activity in MCF-7 breast cancer cells by estrogen and transforming growth factor-beta1.
Downregulation of ER60 Protease Inhibits Cellular Proliferation by Inducing G1/S Arrest in Breast Cancer Cells In Vitro.
Downregulation of ubiquitin-specific protease 14 (USP14) inhibits breast cancer cell proliferation and metastasis, but promotes apoptosis.
Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2.
Effects of an Anticarcinogenic Bowman-Birk Protease Inhibitor on Purified 20S Proteasome and MCF-7 Breast Cancer Cells.
Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer.
Elastosis in breast carcinoma: II. Association of protease inhibitors with immature elastic fibres.
EpCAM associates with endoplasmic reticulum aminopeptidase 2 (ERAP2) in breast cancer cells.
Evidence for tissue factor phosphorylation and its correlation with protease activated receptor expression and the prognosis of primary breast cancer.
Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas.
Hemagglutinin protease secreted by V. cholerae induced apoptosis in breast cancer cells by ROS mediated intrinsic pathway and regresses tumor growth in mice model.
HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
HS3ST2 modulates breast cancer cell invasiveness via MAP kinase- and Tcf4 (Tcf7l2)-dependent regulation of protease and cadherin expression.
Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells.
Identification of a novel aspartic-like protease differentially expressed in human breast cancer cell lines.
Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer.
Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells.
Insulin-like growth factor binding protein (IGFBP)-3 protease activity secreted by MCF-7 breast cancer cells: inhibition by IGFs does not require IGF-IGFBP interaction.
Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer.
Maspin--a novel protease inhibitor with tumor-suppressing activity in breast cancer.
Optical imaging of spontaneous breast tumors using protease sensing 'smart' optical probes.
PAR-1 mediated apoptosis of breast cancer cells by V. cholerae hemagglutinin protease.
Protease Activated Receptors 1 and 2 Correlate Differently with Breast Cancer Aggressiveness Depending on Tumor ER Status.
Protease Activity and Cell-Free DNA in Blood Plasma of Healthy Donors and Breast Cancer Patients.
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients
Protease inhibitor antipain reduces nuclear binding of estrogen-receptor complex in MCF-7 breast tumor cells.
Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
Protease nexin-1 expression is altered in human breast cancer.
Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity.
Protein Z-dependent protease inhibitor (ZPI) is present in loco in human breast cancer tissue.
Re: Selective Inhibition of Her2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir.
Regulation of motility and protease expression in PKC-mediated induction of MCF-7 breast cancer cell invasiveness.
Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion.
Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration.
Secretory Leukocyte Protease Inhibitor (SLPI) expression downregulates E-cadherin, induces ?-catenin re-localisation and triggers apoptosis-related events in breast cancer cells.
Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.
Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells.
Significance of the tumor protease Cathepsin D for the biology of breast cancer.
Structure and putative signaling mechanism of Protease activated receptor 2 (PAR2) - a promising target for breast cancer.
The Association of Protease Activated Receptor 1 gene -506 I/D Polymorphism with Disease-Free Survival in Breast Cancer Patients.
The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway.
The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma.
The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression.
TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells.
Ubiquitin specific protease 21 upregulation in breast cancer promotes cell tumorigenic capability and is associated with the NOD-like receptor signaling pathway.
Ubiquitin-specific protease 4 inhibits breast cancer cell growth through the upregulation of PDCD4.
[Ca(2+)-depend protease (calpain) activity in breast cancer tissue: preliminary report]
Bronchiolitis
[Neutrophil activation and protease imbalance in respiratory tract of infants with respiratory syncytial virus bronchiolitis]
Bronchitis
[Effect of the protease inhibitor aprotinin on pulmonary function and on the inhibitory activity of sputum in patients with chronic obstructive bronchitis]
[Mucous membrane specific protease inhibitors in bronchial mucus in severe chronic obstructive bronchitis and in alpha 1-antitrypsin deficiency syndrome]
Bronchopulmonary Dysplasia
Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia.
Bursitis
Adhesive capsulitis of shoulder and treatment with protease inhibitors in patients with human immunodeficiency virus infection: report of 8 cases.
Adhesive capsulitis of the shoulder induced by protease inhibitor therapy. Three new cases.
Bilateral frozen shoulder associated with a three-drug regimen including a protease inhibitor in a patient with human immunodeficiency virus infection to the editor.
Frozen shoulder: a new delayed complication of protease inhibitor therapy? .
Septic Bursitis, a Potential Complication of Protease Inhibitor Use in Hepatitis C Virus.
Byssinosis
Airborne dust, its protease content and byssinosis in 'willowing' mills.
Candidiasis
Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy.
Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis.
Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors.
Reduction in oropharyngeal candidiasis following introduction of protease inhibitors.
Candidiasis, Cutaneous
Protease and phospholipase activities of Candida spp. isolated from cutaneous candidiasis.
Candidiasis, Oral
Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects.
Oral candidiasis in HIV+ patients under treatment with protease inhibitors.
Oral thrush and HIV protease inhibitors.
Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons.
Withdrawal of fluconazole suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors.
Carcinogenesis
Antisense RNA-mediated deficiency of the calpain protease, nCL-4, in NIH3T3 cells is associated with neoplastic transformation and tumorigenesis.
Atypical mechanism of NF-?B activation by TRE17/ubiquitin-specific protease 6 (USP6) oncogene and its requirement in tumorigenesis.
Cardamonin inhibited cell viability and tumorigenesis partially through blockade of testes-specific protease 50-mediated nuclear factor-kappaB signaling pathway activation.
Change of polyamine content in mouse skin by leupeptin, a protease inhibitor, during early stage of tumorigenesis.
Effect of the synthetic protease inhibitor [N,N-dimethylcarbamoyl-methyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on carcinogenesis by 3-methylcholanthrene in mouse skin.
Effects of various preparations of dietary protease inhibitors on oral carcinogenesis in hamsters induced by DMBA.
Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR/PI3K/AKT drives breast carcinogenesis.
Induction of a novel Ca2+-dependent protease in preneoplastic and neoplastic liver tissues during rat liver carcinogenesis.
Inhibition of 7,12-dimethylbenz[alpha]anthracene-induced mammary tumorigenesis in rats by a synthetic protease inhibitor, N,N-dimethylamino-(p-(p'-guanidinobenzoyloxy)) benzilcarbonyloxyglycolate.
Inhibition of oral carcinogenesis by a protease inhibitor.
Inhibition of tumorigenesis in mouse skin by leupeptin, a protease inhibitor from Actinomycetes.
Knockdown of ubiquitin-specific protease 14 (USP14) inhibits the proliferation and tumorigenesis in esophageal squamous cell carcinoma cells.
Prevention of carcinogenesis by protease inhibitors.
Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine.
Protease inhibitors and carcinogenesis: a review.
Protease inhibitors in carcinogenesis: possible sites of action.
Protease inhibitors in oral carcinogenesis and chemoprevention.
Protease inhibitors interfere with the necessary factors of carcinogenesis.
Secretory leukocyte protease inhibitor modulates urethane-induced lung carcinogenesis.
Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma.
Soybean protease inhibitors and pancreatic carcinogenesis.
Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor.
The field bean protease inhibitor can effectively suppress 7,12-dimethylbenz[a]anthracene-induced skin tumorigenesis in mice.
The role of sentrin-specific protease 2 substrate recognition in TGF-?-induced tumorigenesis.
TSP50 Depends on Its Threonine Protease Activity and Its Interactions with TNF-?-Induced NF-?B for Its Role in Human Cervical Tumorigenesis.
Ubiquitin Specific Protease 26 (USP26) expression analysis in human testicular and extragonadal tissues indicates diverse action of USP26 in cell differentiation and tumorigenesis.
Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis.
Ubiquitin-specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis.
[Effect of synthetic protease inhibitor on the oncogenesis of pancreatic cancer in hamsters: study on pancreatic endocrine cells and free radicals]
Carcinoma
A cytosol protease from the estrogen-resistant C3H mammary carcinoma increases the affinity of the estrogen receptor for DNA in vitro.
A metabolomics investigation into the effects of HIV protease inhibitors on HPV16 E6 expressing cervical carcinoma cells.
A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.
Acid stable protease inhibitor in ascites of ovarian carcinoma.
Activation of actin-cleavable interleukin 1beta-converting enzyme (ICE) family protease CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells.
Association and dissociation of a protease and its inhibitor on the surface of lung squamous cell carcinoma cells.
Association between Time on Protease Inhibitors and the Incidence of Squamous Cell Carcinoma of the Anus among U.S. Male Veterans.
Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma.
Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3).
Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma.
Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model.
Decreased H2B monoubiquitination and overexpression of ubiquitin-specific protease enzyme 22 in malignant colon carcinoma.
Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum.
Differences in genetic variation in antigen-processing machinery components and association with cervical carcinoma risk in two Indonesian populations.
Differential expression of protease activity in serum samples of prostate carcinoma patients with metastases.
Differential protease expression by cutaneous squamous and basal cell carcinomas.
Effect of a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on the growth of mouse skin carcinoma in the rapid growing stage.
Effect of oral administration of protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on the growth of 3-methylcholanthrene-induced carcinoma in mice.
Endoplasmic reticulum aminopeptidase 2 involvement in metastasis of oral cavity squamous cell carcinoma discovered by proteome profiling of primary cancer cells.
Establishment of a new human cancer cell line secreting protease nexin-II/amyloid beta protein precursor derived from squamous-cell carcinoma of lung.
Further purification and characterization of acid-stable protease inhibitor from ascites of an ovarian carcinoma patient.
Genetic variation of antigen processing machinery components and association with cervical carcinoma.
High density of tryptase-positive mast cells in patients with renal cell carcinoma on hemodialysis: correlation with expression of stem cell factor and protease activated receptor-2.
High Expression of Ubiquitin-Specific Protease 8 (USP8) Is Associated with Poor Prognosis in Patients with Cervical Squamous Cell Carcinoma.
Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells.
Identification and characterization of a Kunitz-type protease inhibitor in ascites fluid from patients with ovarian carcinoma.
Isolation of a protease from the cell-free medium of in vitro cultured mammary carcinoma.
Knockdown of ubiquitin-specific protease 14 (USP14) inhibits the proliferation and tumorigenesis in esophageal squamous cell carcinoma cells.
Laminin-1 and SIKVAV a laminin-1-derived peptide, regulate the morphology and protease activity of a human salivary gland adenoid cystic carcinoma cell line.
Laminin-derived peptide AG73 regulates migration, invasion, and protease activity of human oral squamous cell carcinoma cells through syndecan-1 and beta1 integrin.
microRNA-186 Suppresses Cell Proliferation and Metastasis Through Targeting Sentrin Specific Protease 1 in Renal Cell Carcinoma.
miR-186 promotes tumor growth in cutaneous squamous cell carcinoma by inhibiting apoptotic protease activating factor-1.
Molecular backgrounds of ERAP1 downregulation in cervical carcinoma.
mRNA expression and hypermethylation of tumor suppressor genes apoptosis protease activating factor-1 and death-associated protein kinase in oral squamous cell carcinoma.
Narrowing of the region of allelic loss in 21q11-21 in squamous non-small cell lung carcinoma and cloning of a novel ubiquitin-specific protease gene from the deleted segment.
Naturally occurring ERAP1 haplotypes encode functionally distinct alleles with fine substrate specificity.
Neutrophil cathepsin G, but not elastase, induces aggregation of MCF-7 mammary carcinoma cells by a protease activity-dependent cell-oriented mechanism.
Overexpression of protease nexin-1 mRNA and protein in oral squamous cell carcinomas.
Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women.
Presence of alpha-1-antitrypsin in pancreatic carcinoma. Report of four cases in association with hepatic storage of the protease inhibitor.
Protease and antiprotease concentrations in serum and vaginal fluid of patients with carcinoma of the cervix.
Protease and plasminogen activator activity in human bladder carcinoma.
Protease inhibitors and carcinoma of the esophagus.
Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells.
Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants.
Reverse-zymographic analysis of protease nexin-II/amyloid beta protein precursor of human carcinoma cell lines, with special reference to the grade of differentiation and metastatic phenotype.
Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma.
SIKVAV, a laminin alpha1-derived peptide, interacts with integrins and increases protease activity of a human salivary gland adenoid cystic carcinoma cell line through the ERK 1/2 signaling pathway.
SIKVAV, a Laminin {alpha}1-Derived Peptide, Interacts with Integrins and Increases Protease Activity of a Human Salivary Gland Adenoid Cystic Carcinoma Cell Line through the ERK 1/2 Signaling Pathway.
Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma.
Spatial distribution of endogenous tissue protease activity in gastric carcinoma mapped by MALDI mass spectrometry imaging.
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
The antileukoprotease secretory leukocyte protease inhibitor (SLPI) and its role in the prevention of HPV-infections in head and neck squamous cell carcinoma.
The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase-1 in DLD-1 colon carcinoma cells.
The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma.
The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma.
The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostatic carcinoma cell lines, DU145 and LNCaP.
The protease activated receptor 1 gene variation IVSn -14A>T is associated with distant metastasis and cancer-specific survival in renal cell carcinoma.
Two-dimensional polyacrylamide gel electrophoresis of the protease SP220K, a renal cell carcinoma marker.
Ubiquitin-specific protease 14 regulates cell proliferation and apoptosis in oral squamous cell carcinoma.
Ubiquitin-specific protease 4 promotes TNF-?-induced apoptosis by deubiquitination of RIP1 in head and neck squamous cell carcinoma.
Verapamil inhibits tumor protease production, local invasion and metastasis development in murine carcinoma cells.
Viola Yedoensis Suppresses Cell Invasion by Targeting the Protease and NF-?B Activities in A549 and Lewis Lung Carcinoma Cells.
[Effect of the protease inhibitor kontrikal on the transplantability and growth of a solid Ehrlich carcinoma in mice]
[Expression and significance of differentially expressed protein endoplasmic reticulum aminopeptidase 1 in ovarian carcinoma with lymph node metastasis.]
[Serum content and urinary elimination of leucine-aminopeptidase in women with carcinoma of the uterine cervix.]
[Studies on protease in Ehrlich ascites carcinoma cells.]
Carcinoma, Adenoid Cystic
Laminin-1 and SIKVAV a laminin-1-derived peptide, regulate the morphology and protease activity of a human salivary gland adenoid cystic carcinoma cell line.
SIKVAV, a laminin alpha1-derived peptide, interacts with integrins and increases protease activity of a human salivary gland adenoid cystic carcinoma cell line through the ERK 1/2 signaling pathway.
SIKVAV, a Laminin {alpha}1-Derived Peptide, Interacts with Integrins and Increases Protease Activity of a Human Salivary Gland Adenoid Cystic Carcinoma Cell Line through the ERK 1/2 Signaling Pathway.
Carcinoma, Basal Cell
Differential protease expression by cutaneous squamous and basal cell carcinomas.
The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma.
Carcinoma, Ductal
Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers.
Carcinoma, Ehrlich Tumor
Effect of protease and protease inhibitors on the adhesion of Ehrlich ascites tumour cells to plastic.
Inhibition properties of Sepharose-bound trypsin and a protease on the surface of Ehrlich ascites tumour cells.
Size of native and denatured DNA of Ehrlich ascites tumour cells isolated in the presence of different protease concentrations.
Carcinoma, Embryonal
Appearance of nuclear protease activity after embryonal carcinoma cells undergo differentiation.
Carcinoma, Endometrioid
Expression of adipocyte-derived leucine aminopeptidase in endometrial cancer. Association with tumor grade and CA-125.
Possible involvement of adipocyte-derived leucine aminopeptidase via angiotensin II in endometrial carcinoma.
Carcinoma, Hepatocellular
Activity of chromatin-bound protease from rat liver and Morris hepatomas.
Activity-based proteome profiling of hepatoma cells during hepatitis C virus replication using protease substrate probes.
Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells.
Changes in serum protease inhibitors in patients with hepatoma.
Clinical Significance of Ubiquitin Specific Protease 7 (USP7) in Predicting Prognosis of Hepatocellular Carcinoma and its Functional Mechanisms.
Correction: The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation.
Differential analysis of N-glycoproteome between hepatocellular carcinoma and normal human liver tissues by combination of multiple protease digestion and solid phase based labeling.
Differential susceptibilities of murine hepatoma 1c1c7 and Tao cells to the lysosomal photosensitizer NPe6: influence of aryl hydrocarbon receptor on lysosomal fragility and protease contents.
Effect of protease inhibitors on albumin secretion in hepatoma cells.
Functional alpha 1 protease inhibitor produced by a human hepatoma cell line.
ICE-like protease (caspase) is involved in transforming growth factor beta1-mediated apoptosis in FaO rat hepatoma cell line.
Inhibition of insulin degradation by hepatoma cells after microinjection of monoclonal antibodies to a specific cytosolic protease.
Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor.
Oxidative stress and activation of proteasome protease during serum deprivation-induced apoptosis in rat hepatoma cells; inhibition of cell death by melatonin.
Reduced ubiquitin-specific protease 9X expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cells.
Secretion of extracellular matrix (fibronectin), growth factor (transforming growth factor beta) and protease (cathepsin D) by hepatoma cells.
Serum protease inhibitors in opisthorchiasis, hepatoma, cholangiocarcinoma, and other liver diseases.
Studies on the mechanisms of invasion in cancer. 3. Purification of a neutral protease of rat ascites hepatoma cell associated with production of chemotactic factor for cancer cells.
The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation.
The HIV protease inhibitor indinavir impairs glycogen synthesis in HepG2 hepatoma cells.
Ubiquitin-speci?c protease 4 promotes metastasis of hepatocellular carcinoma by increasing TGF-? signaling-induced epithelial-mesenchymal transition.
Ubiquitin-specific protease 11 serves as a marker of poor prognosis and promotes metastasis in hepatocellular carcinoma.
Ubiquitin-specific protease 4 promotes hepatocellular carcinoma progression via cyclophilin A stabilization and deubiquitination.
Ubiquitin-specific protease 7 accelerates p14(ARF) degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression.
[Clinical studies of serum protease inhibitors in hepatoma]
[Effect of protease activated receptor-2 agonists on proliferation of hepatoma cells.]
Carcinoma, Lewis Lung
Viola Yedoensis Suppresses Cell Invasion by Targeting the Protease and NF-?B Activities in A549 and Lewis Lung Carcinoma Cells.
Carcinoma, Non-Small-Cell Lung
A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.
Differential regulation of protease and extracellular matrix protein expression by transforming growth factor-beta 1 in non-small cell lung cancer cells and normal human bronchial epithelial cells.
Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.
Nuclear localization of apoptosis protease activating factor-1 predicts survival after tumor resection in early-stage non-small cell lung cancer.
Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer.
Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.
Protease Serine S1 Family Member 8 (PRSS8) Inhibits Tumor Growth In Vitro and In Vivo in Human Non-Small Cell Lung Cancer.
Testes-specific protease 50 as an independent risk factor for poor prognosis in patients with non-small cell lung cancer.
Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14.
[A study on the relationship between endoplasmic reticulum aminopeptidase2 genetic polymorphisms and non-small cell lung cancer in Yunnan Han population].
Carcinoma, Ovarian Epithelial
Protease inhibitor SERPINA1 expression in epithelial ovarian cancer.
Ubiquitin specific protease 22 promotes cell proliferation and tumor growth of epithelial ovarian cancer through synergy with transforming growth factor ?1.
Ubiquitin-specific protease 14 (USP14) regulates cellular proliferation and apoptosis in epithelial ovarian cancer.
Ubiquitin-specific protease 7 expression is a prognostic factor in epithelial ovarian cancer and correlates with lymph node metastasis.
Carcinoma, Renal Cell
High density of tryptase-positive mast cells in patients with renal cell carcinoma on hemodialysis: correlation with expression of stem cell factor and protease activated receptor-2.
microRNA-186 Suppresses Cell Proliferation and Metastasis Through Targeting Sentrin Specific Protease 1 in Renal Cell Carcinoma.
The protease activated receptor 1 gene variation IVSn -14A>T is associated with distant metastasis and cancer-specific survival in renal cell carcinoma.
Two-dimensional polyacrylamide gel electrophoresis of the protease SP220K, a renal cell carcinoma marker.
Carcinoma, Squamous Cell
Association and dissociation of a protease and its inhibitor on the surface of lung squamous cell carcinoma cells.
Association between Time on Protease Inhibitors and the Incidence of Squamous Cell Carcinoma of the Anus among U.S. Male Veterans.
Endoplasmic reticulum aminopeptidase 2 involvement in metastasis of oral cavity squamous cell carcinoma discovered by proteome profiling of primary cancer cells.
High Expression of Ubiquitin-Specific Protease 8 (USP8) Is Associated with Poor Prognosis in Patients with Cervical Squamous Cell Carcinoma.
HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress.
Laminin-derived peptide AG73 regulates migration, invasion, and protease activity of human oral squamous cell carcinoma cells through syndecan-1 and beta1 integrin.
miR-186 promotes tumor growth in cutaneous squamous cell carcinoma by inhibiting apoptotic protease activating factor-1.
mRNA expression and hypermethylation of tumor suppressor genes apoptosis protease activating factor-1 and death-associated protein kinase in oral squamous cell carcinoma.
Overexpression of protease nexin-1 mRNA and protein in oral squamous cell carcinomas.
Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women.
Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma.
The antileukoprotease secretory leukocyte protease inhibitor (SLPI) and its role in the prevention of HPV-infections in head and neck squamous cell carcinoma.
The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma.
Ubiquitin-specific protease 14 regulates cell proliferation and apoptosis in oral squamous cell carcinoma.
Ubiquitin-specific protease 4 promotes TNF-?-induced apoptosis by deubiquitination of RIP1 in head and neck squamous cell carcinoma.
Cardiomegaly
Ubiquitin-specific protease 14 regulates cardiac hypertrophy progression by increasing GSK-3? phosphorylation.
Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Pathological Cardiac Hypertrophy.
Cardiomyopathies
Calcium-activated protease in hamster cardiomyopathy.
Implications of protease activation in cardiac dysfunction and development of genetic cardiomyopathy in hamsters.
Severe dystrophic cardiomyopathy caused by the enteroviral protease 2A-mediated C-terminal dystrophin cleavage fragment.
[Instability of alpha-2-macroglobulin protease complex in familial cardiomyopathy]
Cardiomyopathy, Dilated
HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.
Cardiotoxicity
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Cardiovascular Diseases
A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors.
Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
Coagulation factor and protease pathways in thrombosis and cardiovascular disease.
HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease.
HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system.
HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease.
Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases.
Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.
Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult spectrum of disease cohort.
Subclinical cardiovascular disease in patients starting contemporary protease inhibitors.
Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases.
Carotid Artery Diseases
Profiling of Atherosclerotic Lesions by Gene and Tissue Microarrays Reveals PCSK6 as a Novel Protease in Unstable Carotid Atherosclerosis.
Carpal Tunnel Syndrome
Carpal tunnel syndrome in HIV-1 patients: a metabolic consequence of protease inhibitor use?
Castleman Disease
No effect of protease inhibitor on clinical and virological evolution of Castleman's disease in an HIV-1-infected patient.
Cataract
Comparison in effect of different metal ions, pH and reducing agent on the protease activity in human hyper mature and mature cataract.
Protein oxidation and loss of protease activity may lead to cataract formation in the aged lens.
Secreted leukocyte protease inhibitor is present in aqueous humours from cataracts and other eye pathologies.
Celiac Disease
Decreased expression of protease inhibitor 9, a granzyme B inhibitor, in celiac disease: a potential mechanism in enterocyte destruction and villous atrophy.
Cerebral Hemorrhage
Bacillus anthracis Protease InhA Increases Blood-Brain Barrier Permeability and Contributes to Cerebral Hemorrhages.
Increased Expression of Ubiquitin-Specific Protease 4 Participates in Neuronal Apoptosis After Intracerebral Hemorrhage in Adult Rats.
Protease activated receptor 1 (PAR1) enhances Src-mediated tyrosine phosphorylation of NMDA receptor in intracerebral hemorrhage (ICH).
The expression and the role of protease nexin-1 on brain edema after intracerebral hemorrhage.
Cerebral Small Vessel Diseases
HIV protease inhibitor exposure predicts cerebral small vessel disease.
Cervical Intraepithelial Neoplasia
ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism.
HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges.
Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women.
Chagas Disease
A target within the target: probing cruzain's P1' site to define structural determinants for the Chagas' disease protease.
[Cysteine-dependent protease in Trypanosoma cruzi useful for the diagnosis of Chagas disease]
Cheilitis
Increased mast cell density and protease content in actinic cheilitis.
Protease inhibitor-related paronychia, ingrown toenails, desquamative cheilitis and cutaneous xerosis.
Cholangiocarcinoma
Serum protease inhibitors in opisthorchiasis, hepatoma, cholangiocarcinoma, and other liver diseases.
Ubiquitin-specific protease 14 expression associated with intrahepatic cholangiocarcinoma cell differentiation.
Cholelithiasis
Cholelithiasis possibly induced by protease inhibitors in 3 patients.
Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
Cholera
Enterotoxigenicity of mature 45-kilodalton and processed 35-kilodalton forms of hemagglutinin protease purified from a cholera toxin gene-negative Vibrio cholerae non-O1, non-O139 strain.
Cholestasis
[Effect of the protease inhibitor contrical on liver and serum proteolytic enzyme activity in experimental cholestasis]
[Tertiary syphilis with liver gummata]
Cholesteatoma
Expression of secretory leukocyte protease inhibitor in middle ear cholesteatoma.
Cholesteatoma, Middle Ear
Expression of secretory leukocyte protease inhibitor in middle ear cholesteatoma.
Chondrosarcoma
Kunitz-type protease inhibitor bikunin disrupts phorbol ester-induced oligomerization of CD44 variant isoforms containing epitope v9 and subsequently suppresses expression of urokinase-type plasminogen activator in human chondrosarcoma cells.
Chorioamnionitis
Overexpression of histamine H(1)-receptor by human amniotic epithelial cells in chorioamnionitis correlates with augmented production of secretory leukocyte protease inhibitor.
Choriocarcinoma
Endoplasmic reticulum aminopeptidase-1 mediates leukemia inhibitory factor-induced cell surface human leukocyte antigen-G expression in JEG-3 choriocarcinoma cells.
Expression of placental leucine aminopeptidase and adipocyte-derived leucine aminopeptidase in human normal and malignant invasive trophoblastic cells.
Leukemia inhibitory factor triggers activation of signal transducer and activator of transcription 3, proliferation, invasiveness, and altered protease expression in choriocarcinoma cells.
The role of endoplasmic reticulum aminopeptidase 2 in modulating immune detection of choriocarcinoma.
Chronic Periodontitis
Analysis of in situ protease activity in chronic adult periodontitis patients: expression of activated MMP-2 and a 40 kDa serine protease.
Expression of protease activated receptor-1 in chronic periodontitis.
Human ?-defensin 2 and protease activated receptor-2 expression in patients with chronic periodontitis.
Secretory leukocyte protease inhibitor and its potential interactions with elastase and cathepsin B in gingival crevicular fluid and saliva from patients with chronic periodontitis.
The short-term effectiveness of non-surgical treatment in reducing protease activity in gingival crevicular fluid from chronic periodontitis patients.
Towards the definition of a Peptidome Signature and Protease Profile in Chronic Periodontitis.
Classical Swine Fever
Autocatalytic Cleavage within Classical Swine Fever Virus NS3 Leads to a Functional Separation of Protease and Helicase.
Loss of interferon regulatory factor 3 in cells infected with classical swine fever virus involves the N-terminal protease, Npro.
The classical swine fever virus N-terminal protease N(pro) binds to cellular HAX-1.
The influence of protease inhibitors of the organism, especially bovine aprotinin, on the production of virulent hog cholera virus in tissue cultures.
Clostridium Infections
Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen.
Coccidioidomycosis
A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice.
Coccidiosis
Dietary protease can alleviate negative effects of a coccidiosis infection on production performance in broiler chickens
Cockayne Syndrome
Involvement of antipain-sensitive protease activity in the interferon-beta-induced UV-refractoriness of Cockayne syndrome fibroblasts.
Coinfection
Effect of HIV/HCV Co-Infection on the Protease Evolution of HIV-1B: A Pilot Study in a Pediatric Population.
HIV Reverse Transcriptase and Protease Genes Variability Can Be a Biomarker Associated with HIV and Hepatitis B or C Coinfection.
HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians.
Impact of a basement membrane-degrading protease on dissemination and secondary infection of Autographa californica multiple nucleopolyhedrovirus in Heliothis virescens (Fabricus).
Liver fibrosis in HIV/hepatitis C coinfection: HIV protease inhibitors may be protective.
Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection.
Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.
Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women.
Colic
[Renal colic and lithiasis in HIV(+)-patients treated with protease inhibitors]
Colitis
Increased Pancreatic Protease Activity in Response to Antibiotics Impairs Gut Barrier and Triggers Colitis.
Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis.
Unconjugated bilirubin ameliorates the inflammation and digestive protease increase in TNBS-induced colitis.
Colitis, Ulcerative
Correlation of thrombotic thrombocytopenic purpura disease activity with von Willibrand factor-cleaving protease level in ulcerative colitis.
Protease activity in a hapten-induced model of ulcerative colitis in rats.
Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients.
Colonic Neoplasms
A Clinical Wide-Field Fluorescence Endoscopic Device for Molecular Imaging Demonstrating Cathepsin Protease Activity in Colon Cancer.
Activated protease receptor-2 induces GATA6 expression to promote survival in irradiated colon cancer cells.
Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations.
Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: implications for coagulation regulation on tumor cells.
Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer.
Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement.
Legume seeds and colorectal cancer revisited: Protease inhibitors reduce MMP-9 activity and colon cancer cell migration.
LonP1 Differently Modulates Mitochondrial Function and Bioenergetics of Primary Versus Metastatic Colon Cancer Cells.
The anti-proliferative effect of TI1B, a major Bowman-Birk isoinhibitor from pea (Pisum sativum L.), on HT29 colon cancer cells is mediated through protease inhibition.
The protective role of the Bowman-Birk protease inhibitor in soybean lunasin digestion: the effect of released peptides on colon cancer growth.
[Protease activities in gastric and colon cancer tissues]
Colorectal Neoplasms
Enhanced activity of meprin-?, a pro-migratory and pro-angiogenic protease, in colorectal cancer.
Expression of protease activated receptor-2 in human colorectal cancer and its association with tumor progression.
Expression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancer.
Functional protease profiling with reporter peptides in serum specimens of colorectal cancer patients: demonstration of its routine diagnostic applicability.
High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma.
Hypoxia induces epithelial-mesenchymal transition in colorectal cancer cells through ubiquitin-specific protease 47-mediated stabilization of Snail: A potential role of Sox9.
Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer.
Induction of protective antitumor immunity through attenuation of ERAAP function.
Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth.
Legume seeds and colorectal cancer revisited: Protease inhibitors reduce MMP-9 activity and colon cancer cell migration.
Secretion of protease nexin-II/amyloid beta protein precursor by human colorectal carcinoma cells and its modulation by cytokines/growth factors and proteinase inhibitors.
Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.
Ubiquitin specific protease 4 positively regulates the WNT/?-catenin signaling in colorectal cancer.
Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases.
Common Cold
Proteolytic activity and serum protease inhibitors in nasal secretions from adult patients with common colds.
Communicable Diseases
Infectious disease: 3D structure of Zika virus protease.
Influence of ERAP1 and ERAP2 gene polymorphisms on disease susceptibility in different populations.
Polymorphisms in ERAP1 and ERAP2 are shared by Caninae and segregate within and between random- and pure-breeds of dogs.
Proteases and protease inhibitors in infectious diseases.
[Impact of protease inhibitors on hospitalization in an Infectious Disease Unit]
[Usefulness of a protease inhibitor (urinastatin) in ARDS with infectious diseases]
Conjunctivitis, Allergic
Increased conjunctival expression of protease activated receptor 2 (PAR-2) in seasonal allergic conjunctivitis: a role for abnormal conjunctival epithelial permeability in disease pathogenesis?
The effect of topically applied secretory leukocyte protease inhibitor on the eosinophil response in the late phase of allergic conjunctivitis.
Corneal Injuries
Characterization of rabbit corneal damage produced by Serratia keratitis and by a serratia protease.
Corneal Ulcer
Effect of phosphoramidon on protection against corneal ulcer caused by elastase and protease from Pseudomonas aeruginosa.
Coronary Artery Disease
Coronary artery disease occurring with protease inhibitor therapy.
Left main coronary artery disease in a 40-year-old man receiving HIV protease inhibitors.
Severe premature coronary artery disease with protease inhibitors.
[Protease inhibitors and ectasia in coronary atherosclerosis]
Coronary Disease
A comparison of different protease inhibitors on coronary heart disease risk.
Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: report of four cases and review.
HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure.
Protease variants, LDL, and coronary heart disease.
Coronary Occlusion
Effect of NCO-700, an inhibitor of protease, on myocardial pH decreased by coronary occlusion in dogs.
Coronavirus Infections
Correction: Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.
Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.
Craniocerebral Trauma
Brain protease activity after experimental head injury.
Creutzfeldt-Jakob Syndrome
Coexistence of protease sensitive and resistant prion protein in 129VV homozygous sporadic Creutzfeldt-Jakob disease: a case report.
Effect of protease treatment on plasma infectivity in variant Creutzfeldt-Jakob disease mice.
The prion protein protease sensitivity, stability and seeding activity in variably protease sensitive prionopathy brain tissue suggests molecular overlaps with sporadic Creutzfeldt-Jakob disease.
Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay.
Type 1 protease resistant prion protein and valine homozygosity at codon 129 of PRNP identify a subtype of sporadic Creutzfeldt-Jakob disease.
Crohn Disease
Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease.
Number, fixation properties, dye-binding and protease expression of duodenal mast cells: comparisons between healthy subjects and patients with gastritis or Crohn's disease.
The putative role of endoplasmic reticulum aminopeptidases in autoimmunity: Insights from genomic-wide association studies.
Cryoglobulinemia
Arthralgias and cryoglobulinemia during protease inhibitor therapy in a patient infected with human immunodeficiency virus and hepatitis C virus.
Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir.
Cryptosporidiosis
Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors.
[Cryptosporidium infection: value of a protease inhibitor]
Cushing Syndrome
Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent.
Development of Iatrogenic Cushing Syndrome After Peri-articular Glucocorticoid Injection in an Human Immunodeficiency Virus Patient on Protease Inhibitor Therapy.
Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy.
Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.
Iatrogenic hypercortisolism complicating triamcinolone acetonide injections in patients with HIV on ritonavir-boosted protease inhibitors.
Visceral obesity, hypertriglyceridemia and hypercortisolism in a boy with perinatally acquired HIV infection receiving protease inhibitor-containing antiviral treatment.
Cutis Laxa
Elastase-like protease and elastolytic activities expressed in cultured dermal fibroblasts derived from lesional skin of patients with pseudoxanthoma elasticum, actinic elastosis, and cutis laxa.
Cystic Fibrosis
A Protease Inhibitor Tackles Epithelial Sodium Channels in Cystic Fibrosis.
Amniotic fluid protease activity and the prenatal detection of cystic fibrosis.
Analysis of fetal intestinal enzymes in amniotic fluid for the prenatal diagnosis of cystic fibrosis.
Cystic fibrosis alpha 2-macroglobulin protease interaction in vitro.
Cystic fibrosis sputum induces a secretory response from airway gland serous cells that can be prevented by neutrophil protease inhibitors.
Cystic fibrosis: protease activity in saliva evaluated with chromogenic substrates.
Effect of the addition of protease inhibitors to sputa from cystic fibrosis patients.
False positive prenatal diagnosis of cystic fibrosis by protease assay.
Poly-l-Lysine Compacts DNA, Kills Bacteria, and Improves Protease Inhibition in Cystic Fibrosis Sputum.
Prenatal diagnosis of cystic fibrosis by methylumbelliferylguanidinobenzoate protease titration in amniotic fluid.
Protease actions on airway secretions. Relevance to cystic fibrosis.
Protease binding by alpha 2 macroglobulin in cystic fibrosis.
Protease deficiency in plasma of patients with cystic fibrosis. Reduced reaction of 4-methylumbelliferylguanidinobenzoate with plasma of patients with cystic fibrosis.
Protease inhibitor and defective proteolysis in cystic fibrosis.
Protease phenotypes of Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
Protease production by Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
Pseudomonas aeruginosa LasB protease impairs innate immunity in mice and humans by targeting a lung epithelial cystic fibrosis transmembrane regulator-IL-6-antimicrobial-repair pathway.
Screening for cystic fibrosis by analysis of meconium for albumin and protease inhibitors.
Secretory leukocyte protease inhibitor in cystic fibrosis.
The Pseudomonas aeruginosa secretory product pyocyanin inactivates alpha1 protease inhibitor: implications for the pathogenesis of cystic fibrosis lung disease.
Cystitis
Graft pancreatitis and hemorrhagic cystitis. Treatment with bladder irrigation and protease inhibition.
Up-regulation of protease activated receptors in bladder after cyclophosphamide induced cystitis and colocalization with capsaicin receptor (VR1) in bladder nerve fibers.
Cysts
Heat treatment affects protein quality and protease activity in decapsulated cysts of Artemia when used as starter food for larvae of African catfish Clarias gariepinus (Burchell).
Protease inhibitor expression in soybean roots exhibiting susceptible and resistant interactions with soybean cyst nematode.
Purification and characterization of a cytosol protease from dormant cysts of the brine shrimp Artemia.
Retargeting of a Plant Defense Protease by a Cyst Nematode Effector.
Sensitivity of Vermamoeba (Hartmannella) vermiformis cysts to conventional disinfectants and protease.
Cytomegalovirus Infections
Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100 x 10(6) cells/l following combination antiretroviral therapy including protease inhibitors.
Cytomegalovirus Retinitis
Cystoid macular edema in a patient with acquired immunodeficiency syndrome and past ocular history of cytomegalovirus retinitis after initiation of protease inhibitors.
Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years.
Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors.
Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. Spanish CMV-AIDS Study Group.
Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors.
Protease inhibitor therapy is associated with markedly prolonged time to relapse and improved survival in AIDS patients with cytomegalovirus retinitis.
[Impact of anti-retroviral treatment with protease inhibitors on the evolution of cytomegalovirus retinitis in the patient carrying acquired immunodeficiency syndrome]
Dandruff
Retention of corneodesmosomes and increased expression of protease inhibitors in dandruff.
Deafness
Insertion of beta-satellite repeats identifies a transmembrane protease causing both congenital and childhood onset autosomal recessive deafness.
Dehydration
A Brassica napus transcript encoding a protein related to the Künitz protease inhibitor family accumulates upon water stress in leaves, not in seeds.
Analysis of secreted protease inhibitors after water stress in potato tubers.
Autoprocessing of the protease that degrades small, acid-soluble proteins of spores of Bacillus species is triggered by low pH, dehydration, and dipicolinic acid.
Dementia
Amyloid-beta deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in AbetaPP mRNA isoforms containing the Kunitz protease inhibitor.
Clinical course and CSF amyloid beta protein precursor having the site of application of the protease inhibitor (APPI) levels in patients with dementia of the Alzheimer type.
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia.
Protease inhibitors may reverse AIDS dementia.
Upregulation of amyloid precursor protein isoforms containing Kunitz protease inhibitor in dementia with Lewy bodies.
Demyelinating Diseases
Effect of cyclosporin A, silica quartz dust, and protease inhibitors on virus-induced demyelination.
Implications of protease M/neurosin in myelination during experimental demyelination and remyelination.
Mitosis of Schwann cells and demyelination are induced by the amyloid precursor protein and other protease inhibitors in the rat sciatic nerve.
Dengue
3,5-Bis(arylidene)-4-piperidones as potential dengue protease inhibitors.
A comparative biochemical analysis of the NS2B(H)-NS3pro protease complex from four dengue virus serotypes.
A dual-purpose synthetic colloidal platform for protease mapping: substrate profiling for Dengue and West Nile virus proteases.
A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease.
A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture.
A straightforward experimental approach to expression, purification, refolding, and enzymatic analysis of recombinant dengue virus NS2B(H)-NS3pro protease.
Activation of dengue protease autocleavage at the NS2B-NS3 junction by recombinant NS3 and GST-NS2B fusion proteins.
Analysis of the domain interactions between the protease and helicase of NS3 in dengue and hepatitis C virus.
Biochemistry and medicinal chemistry of the dengue virus protease.
C-terminal residue optimization and fragment merging: discovery of a potent Peptide-hybrid inhibitor of dengue protease.
Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro.
Characterization of protease cleavage sites involved in the formation of the envelope glycoprotein and three non-structural proteins of dengue virus type 2, New Guinea C strain.
Cleavage of the dengue virus polyprotein at the NS3/NS4A and NS4B/NS5 junctions is mediated by viral protease NS2B-NS3, whereas NS4A/NS4B may be processed by a cellular protease.
Construction of dengue virus protease expression plasmid and in vitro protease assay for screening antiviral inhibitors.
Correction for Liu et al., "Endoplasmic Reticulum Protein SCAP Inhibits Dengue Virus NS2B3 Protease by Suppressing Its K27-Linked Polyubiquitylation".
Dengue protease activity: the structural integrity and interaction of NS2B with NS3 protease and its potential as a drug target.
Dengue Protease Substrate Recognition: Binding of the Prime Side.
Designing cyclic peptide inhibitor of dengue virus NS3-NS2B protease by using molecular docking approach.
Discovery of Nanomolar Dengue and West Nile Virus Protease Inhibitors Containing a 4-Benzyloxyphenylglycine Residue.
Docking of noncompetitive inhibitors into dengue virus type 2 protease: understanding the interactions with allosteric binding sites.
ER protein SCAP inhibits Dengue virus NS2B3 protease by suppressing its K27-linked polyubiquitylation.
Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications.
Fluorimetric and HPLC-based dengue virus protease assays using a FRET substrate.
Identification of a novel inhibitor of dengue virus protease through use of a virtual screening drug discovery Web portal.
Identification of covalent active site inhibitors of dengue virus protease.
Inhibition of dengue virus replication by novel inhibitors of RNA-dependent RNA polymerase and protease activities.
Ligand-bound structures of the dengue virus protease reveal the active conformation.
Lyso-myristoyl phosphatidylcholine micelles sustain the activity of Dengue non-structural (NS) protein 3 protease domain fused with the full-length NS2B.
New approaches to structure-based discovery of dengue protease inhibitors.
Optimization of Assay Conditions for Dengue Virus Protease: Effect of Various Polyols and Nonionic Detergents.
Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors.
Product release is rate-limiting for catalytic processing by the Dengue virus protease.
Selection of suitable detergents for obtaining an active dengue protease in its natural form from E.coli.
Small molecule inhibitor discovery for dengue virus protease using high-throughput screening.
Structural insights into a multifunctional inhibitor, 'AMTIN' from tubers of Alocasia macrorrhizos and its possible role in dengue protease (NS2B-NS3) inhibition.
Structure-based discovery of dengue virus protease inhibitors.
Structure-guided fragment-based in silico drug design of dengue protease inhibitors.
Structure-guided mutagenesis of active site residues in the dengue virus two-component protease NS2B-NS3.
Synthesis and biological evaluation of ?-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture.
Synthesis and molecular modelling studies of novel sulphonamide derivatives as dengue virus 2 protease inhibitors.
Thiazolidinone-Peptide Hybrids as Dengue Virus Protease Inhibitors with Antiviral Activity in Cell Culture.
Dental Plaque
Relation between the presence of supragingival calculus and protease activity in dental plaque.
Dermatitis
Dermatitis induced by first generation Hepatitis C virus protease inhibitors.
Effects of potato-derived protease inhibitors on perianal dermatitis after colon resection for long-segment Hirschsprung's disease.
Dermatitis, Atopic
A nonsynonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis.
Endoplasmic reticulum aminopeptidase 1 polymorphism Ile276Met is associated with atopic dermatitis and affects the generation of an HLA-C associated antigenic epitope in vitro.
Evidence for degradation of cytokines in the serum of patients with atopic dermatitis by calcium-dependent protease.
Identification of bacterial biofilm and the Staphylococcus aureus derived protease, staphopain, on the skin surface of patients with atopic dermatitis.
Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis.
The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.
The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle-controlled study.
Dermatitis, Contact
Contact dermatitis from B. subtilis-derived protease enzymes.
Diabetes Complications
Protease inhibitor-induced diabetic complications : incidence, management and prevention.
Diabetes Mellitus
Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis.
Complete resolution of protease inhibitor induced diabetes mellitus.
Diabetes mellitus associated with protease inhibitor use.
Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.
Evaluation of aging, diabetes mellitus, and skin wounds by scanning acoustic microscopy with protease digestion.
Expression, genomic structure and mapping of the thymus specific protease prss16: a candidate gene for insulin dependent diabetes mellitus susceptibility.
New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review.
New-onset diabetes mellitus associated with use of protease inhibitor.
Plasma inactive renin in patients with diabetes mellitus: effects of standing and the relation to serum protease inhibitor.
Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus.
Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women.
Protease inhibitor-associated diabetes mellitus: a potential cause of morbidity and mortality.
Protease inhibitors, diabetes mellitus and blood lipids.
Protease profiling of different biofluids in type 1 diabetes mellitus.
Risk factors for new-onset diabetes mellitus in patients receiving protease inhibitor therapy.
[Activity of serum and lymphocyte serine proteases of patients with diabetes mellitus and the possibility of using protease blockers in combined therapy]
[Diabetes mellitus and protease inhibitors. A complication to take into account]
[Diabetes mellitus associated with protease inhibitors in HIV infected patients]
[Protease inhibitor-associated hypertriglyceridemia and diabetes mellitus in HIV-infected patients]
Diabetes Mellitus, Experimental
[Effect of bacterial protease and alloxan diabetes on wound healing in the gingiva of rats]
Diabetes Mellitus, Type 1
Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity.
Insulin-like growth factor binding proteins (IGFBPs) in serum and urine and IGFBP-2 protease activity in patients with insulin-dependent diabetes mellitus.
Protease profiling of different biofluids in type 1 diabetes mellitus.
The putative role of endoplasmic reticulum aminopeptidases in autoimmunity: Insights from genomic-wide association studies.
Diabetes Mellitus, Type 2
The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes.
Diabetic Foot
Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing.
Expression of Matrix-Metalloproteases in the Fluid of Chronic Diabetic Foot Wounds Treated with a Protease Absorbent Dressing.
Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers.
The Effectiveness of Negative Pressure Therapy in Diabetic Foot Ulcers with Elevated Protease Activity: A Case Series.
Diabetic Ketoacidosis
Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance.
Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis.
Diabetic Nephropathies
Erratum: Protease activated receptor 2 in diabetic nephropathy: a double edged sword.
Protease activated receptor 2 in diabetic nephropathy: a double edged sword.
Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy.
Disseminated Intravascular Coagulation
Effects of FUT-175, a new synthetic protease inhibitor on endotoxin-induced disseminated intravascular coagulation in rats.
Prevention of the liquoid-induced consumption coagulopathy by the protease inhibitor aprotinin.
Protective effects of ONO-3307, a new synthetic protease inhibitor against experimental disseminated intravascular coagulation in rats.
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
[Protease inhibitors and plasminogen in leukemia--with special reference to disseminated intravascular coagulation (author's transl)]
[Synthetic protease inhibitors in the treatment of disseminated intravascular coagulation]
[The protease inhibitor treatment of the disseminated intravascular coagulation syndrome in patients with liver cirrhosis]
Down Syndrome
Alpha-1-antitrypsin protease inhibitor (Pi) phenotypes in Down's syndrome patients and their parents.
High expression on Kunitz-type protease inhibitor-containing substances in the cerebral vessels of patients with Down syndrome.
Drug Eruptions
Fixed drug eruptions to human immunodeficiency virus-1 protease inhibitor.
Drug-Related Side Effects and Adverse Reactions
Adverse drug reactions to protease inhibitors.
Cost of Adverse Drug Reactions (ADR) with Protease Inhibitors in the Treatment of Hepatitis C in the Health System of Extremadura (SES).
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.
Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort.
Duodenal Obstruction
Continuous regional application of protease inhibitor in the treatment of acute pancreatitis. An experimental study using closed duodenal obstruction model in dogs.
Duodenal Ulcer
Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer.
[Blood protease inhibitors in children with duodenal ulcer and gastroduodenitis during health resort therapy]
Dyslipidemias
Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Dyslipidemia due to retroviral protease inhibitors.
Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens.
Dyslipidemia in the era of HIV protease inhibitors.
Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial.
Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors.
Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones.
HIV protease inhibitors and dyslipidemia.
HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.
Impact of cocaine use on protease inhibitor-associated dyslipidemia in HIV-infected adults.
Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.
Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir.
Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice.
Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia.
Management of dyslipidemia associated with protease inhibitors.
Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen.
Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice.
Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by the APOA5-1131T->C Gene Variation.
Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats.
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice.
The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727 McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase Subtilisin/Kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012. [Epub ahead of print].
Elephantiasis, Filarial
Identification of 38kDa Brugia malayi microfilarial protease as a vaccine candidate for lymphatic filariasis.
Encephalitis
Cerebrospinal fluid viral escape and acute encephalitis in a patient on boosted protease inhibitor monotherapy.
Improvement of the purification of Saint Louis encephalitis virus NS2B-NS3 recombinant protease expressed in Escherichia coli.
Protease treatment and chemical crosslinking of a flavivirus: tick borne encephalitis virus.
Solid-phase synthesis and screening of a library of C-terminal arginine peptide aldehydes against Murray Valley encephalitis virus protease.
Unexpected altered specificity is responsible for St. Louis encephalitis virus recombinant protease autoproteolysis.
Encephalitis, Japanese
Enzymatic analysis of recombinant Japanese encephalitis virus NS2B(H)-NS3pro protease with fluorogenic model peptide substrates.
Encephalitis, St. Louis
Improvement of the purification of Saint Louis encephalitis virus NS2B-NS3 recombinant protease expressed in Escherichia coli.
Encephalitis, Tick-Borne
Changing the protease specificity for activation of a flavivirus, tick-borne encephalitis virus.
Protease treatment and chemical crosslinking of a flavivirus: tick borne encephalitis virus.
Encephalomyelitis
Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine.
Protease activated receptor-1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood-brain barrier.
The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis.
Time-dependent increases in protease activities for neuronal apoptosis in spinal cords of Lewis rats during development of acute experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis.
Protease activated receptor-1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood-brain barrier.
Suppression of experimental allergic encephalomyelitis (EAE) with liposome-encapsulated protease inhibitor: therapy through the blood-brain barrier.
The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis.
Time-dependent increases in protease activities for neuronal apoptosis in spinal cords of Lewis rats during development of acute experimental autoimmune encephalomyelitis.
Endocarditis
Modulation of glycosidase and protease activities by chemostat growth conditions in an endocarditis strain of Streptococcus sanguis.
Role of vegetation-associated protease activity in valve destruction in human infective endocarditis.
Endocarditis, Subacute Bacterial
Protease production by Streptococcus sanguis associated with subacute bacterial endocarditis.
Endometrial Neoplasms
Adipocyte-derived leucine aminopeptidase suppresses angiogenesis in human endometrial carcinoma via renin-angiotensin system.
Expression of adipocyte-derived leucine aminopeptidase in endometrial cancer. Association with tumor grade and CA-125.
Expression of protease activated receptor-2 related to angiogenesis in tumor advancement of uterine endometrial cancers.
Lysosomal protease cathepsin D is a prognostic marker in endometrial cancer.
MiR-148b functions as a tumor suppressor by targeting endoplasmic reticulum metallo protease 1 in human endometrial cancer cells.
Possible involvement of adipocyte-derived leucine aminopeptidase via angiotensin II in endometrial carcinoma.
Progesterone receptor structure and protease activity in primary human endometrial carcinoma.
The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma.
Endometriosis
Association of protease activity against IGFBP-3 with peritoneal fluid mitogens: possible implications for the ectopic growth of endometrial cells in women with endometriosis.
Cathepsin Protease Inhibition Reduces Endometriosis Lesion Establishment.
Elevated Peritoneal Fluid TNF-? Incites Ovarian Early Growth Response Factor 1 Expression and Downstream Protease Mediators: A Correlation With Ovulatory Dysfunction in Endometriosis.
Expression of secretory leukocyte protease inhibitor in women with endometriosis.
Increased concentrations of secretory leukocyte protease inhibitor in peritoneal fluid of women with endometriosis.
Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP-3 protease activity in the peritoneal fluid of patients with and without endometriosis.
Multiplexed protease activity assay for low-volume clinical samples using droplet-based microfluidics and its application to endometriosis.
Protein, progesterone, and protease inhibitors in uterine and peritoneal fluids of women with endometriosis.
Secretory leukocyte protease inhibitor in ovarian endometriomas following GnRH agonist therapy.
[Specific features of protease and antiprotease activity of blood in women with external endometriosis]
endopeptidase la deficiency
Distorted secretory granule composition in mast cells with multiple protease deficiency.
Lysosomal protease deficiency or substrate overload induces an oxidative-stress mediated STAT3-dependent pathway of lysosomal homeostasis.
Plasma therapy in von Willebrand factor protease deficiency.
Protease deficiency in plasma of patients with cystic fibrosis. Reduced reaction of 4-methylumbelliferylguanidinobenzoate with plasma of patients with cystic fibrosis.
Specific protease deficiency in polymorphonuclear leukocytes of Chédiak-Higashi syndrome and beige mice.
The effects of intrinsic pathway protease deficiencies on plasminogen-deficient mice.
[High substitution value of pepsin in gastric protease deficiency.]
Endophthalmitis
Antibiotic susceptibility, cytotoxicity, and protease activity of viridans group streptococci causing endophthalmitis.
Secretory leukocyte protease inhibitor is an inducible antimicrobial peptide expressed in Staphylococcus aureus endophthalmitis.
Endotoxemia
Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia.
Enteritis
Evaluation of high dietary inclusion of distillers dried grains with solubles and supplementation of protease and xylanase in the diets of broiler chickens under necrotic enteritis challenge.
[Research on serum leucine-aminopeptidase during acute enteritis in the infants]
Enzootic Bovine Leukosis
Inhibition of activity of the protease from bovine leukemia virus.
Epidermolysis Bullosa Dystrophica
Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate.
Epidermolysis Bullosa Simplex
Generalized dominant epidermolysis bullosa simplex: decreased activity of a gelatinolytic protease in cultured fibroblasts as a phenotypic marker.
Epilepsy
Activation of CPP-32 protease in hippocampal neurons following ischemia and epilepsy.
Crystal structure of aura virus capsid protease and its complex with dioxane: new insights into capsid-glycoprotein molecular contacts.
Crystallization, high-resolution data collection and preliminary crystallographic analysis of Aura virus capsid protease and its complex with dioxane.
The epilepsy, the protease inhibitor and the dodecamer: progressive myoclonus epilepsy, cystatin b and a 12-mer repeat expansion.
Equine Infectious Anemia
Expression of functional protease and subviral particles by vaccinia virus containing equine infectious anaemia virus gag and 5' pol genes.
Expression of the protease gene of equine infectious anemia virus in Escherichia coli: formation of the mature processed enzyme and specific cleavage of the gag precursor.
Erectile Dysfunction
Protease inhibitors and erectile dysfunction.
Risk factors for sexual and erectile dysfunction in HIV-infected men: the role of protease inhibitors.
Erythema
Effect of serine-type protease of Candida spp. isolated from linear gingival erythema of HIV-positive children: critical factors in the colonization.
Esophageal Diseases
Natural history of HIV-associated esophageal disease in the era of protease inhibitor therapy.
Esophageal Neoplasms
Inhibition of N-nitrosomethylbenzylamine-induced esophageal neoplasms by the Bowman-Birk protease inhibitor.
Relationship between secretory leukocyte protease inhibitor levels in bronchoalveolar lavage fluid and postoperative pulmonary complications in patients with esophageal cancer.
Ubiquitin-specific protease 4 improves the prognosis of the patients in esophageal cancer.
Esophageal Squamous Cell Carcinoma
Knockdown of ubiquitin-specific protease 14 (USP14) inhibits the proliferation and tumorigenesis in esophageal squamous cell carcinoma cells.
Essential Hypertension
Association of single nucleotide polymorphisms in the 3'UTR of ERAP1 gene with essential hypertension in the Northeastern Han Chinese.
Reduced activity of the hypertension-associated Lys528Arg mutant of human adipocyte-derived leucine aminopeptidase (A-LAP)/ER-aminopeptidase-1.
The ERAP2 gene is associated with preeclampsia in Australian and Norwegian populations.
Exanthema
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL).
Familial Primary Pulmonary Hypertension
HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension.
Fascioliasis
The diagnosis of human fascioliasis by enzyme-linked immunosorbent assay (ELISA) using recombinant cathepsin L protease.
Fatty Liver
Coagulation-driven hepatic fibrosis requires protease activated receptor-1 (PAR-1) in a mouse model of TCDD-elicited steatohepatitis.
Is it appropriate to study blood ghrelin and obestatin in non-alcoholic fatty liver disease (NAFLD) without using protease inhibitors?
Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice.
Femur Head Necrosis
[Possible complication of HIV therapy. Protease inhibitor-induced femur head necrosis]
Fetal Growth Retardation
HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction.
Fetal Hypoxia
[Protease inhibitors in the blood serum of parturients in cases of acute and chronic fetal anoxia]
Fibrosarcoma
Integral membrane protease fibroblast activation protein sensitizes fibrosarcoma to chemotherapy and alters cell death mechanisms.
[The effect of collagen and fibrin on the lysosomal protease activities of cultured fibrosarcoma (HT-1080)]
Food Hypersensitivity
Clinical significance of the colonoscopic allergen provocation test.
Colonoscopic allergen provocation (COLAP): a new diagnostic approach for gastrointestinal food allergy.
Evaluation of colonoscopic allergen provocation as a diagnostic tool in dogs with proven food hypersensitivity reactions.
Foodborne Diseases
The protease CspB is essential for initiation of cortex hydrolysis and dipicolinic acid (DPA) release during germination of spores of Clostridium perfringens type A food poisoning isolates.
Foot Ulcer
Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers.
The Effectiveness of Negative Pressure Therapy in Diabetic Foot Ulcers with Elevated Protease Activity: A Case Series.
Foot-and-Mouth Disease
A region of the 5' noncoding region of foot-and-mouth disease virus RNA directs efficient internal initiation of protein synthesis within cells: involvement with the role of L protease in translational control.
A second protease of foot-and-mouth disease virus.
Biologically active protease of foot and mouth disease virus is expressed from cloned viral cDNA in Escherichia coli.
Foot-and-mouth disease virus assembly: processing of recombinant capsid precursor by exogenous protease induces self-assembly of pentamers in vitro in a myristoylation-dependent manner.
Intracellular expression and processing of foot-and-mouth disease virus capsid precursors using vaccinia virus vectors: influence of the L protease.
L protease from foot and mouth disease virus confers eIF2-independent translation for mRNAs bearing picornavirus IRES.
Production of foot-and-mouth disease virus capsid proteins by the TEV protease.
Friedreich Ataxia
Oxidative stress and protease dysfunction in the yeast model of Friedreich ataxia.
Frontotemporal Lobar Degeneration
Secretory Leukocyte Protease Inhibitor Protein Regulates the Penetrance of Frontotemporal Lobar Degeneration in Progranulin Mutation Carriers.
Furunculosis
Differential susceptibility of salmonid fishes to furunculosis correlates with differential serum enhancement of Aeromonas salmonicida extracellular protease activity.
Vaccination of Atlantic salmon against furunculosis with protease of a virulent strain of Aeromonas salmonicida.
Gastritis
Helicobacter pylori-mediated gastritis induces local downregulation of secretory leukocyte protease inhibitor in the antrum.
Number, fixation properties, dye-binding and protease expression of duodenal mast cells: comparisons between healthy subjects and patients with gastritis or Crohn's disease.
Secretory leukocyte protease inhibitor expression in various types of gastritis: a specific role of Helicobacter pylori infection.
Gastroenteritis
Identification of protease and ADP-ribose 1''-monophosphatase activities associated with transmissible gastroenteritis virus non-structural protein 3.
Gastroesophageal Reflux
Gastroesophageal reflux disease does not lead to changes in the secretory leukocyte protease inhibitor expression in esophageal mucosa.
Gastrointestinal Diseases
The current status of alpha-1-antityrpsin, a protease inhibitor, in gastrointestinal disease.
Giant Cell Tumor of Bone
Cathepsin K is the principal protease in giant cell tumor of bone.
Protease expression in giant cell tumour of bone: a comparative study on feline and human samples.
Giant Cell Tumors
Cathepsin K is the principal protease in giant cell tumor of bone.
Protease expression in giant cell tumour of bone: a comparative study on feline and human samples.
Gilbert Disease
Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy--an extended haplotype of genetic variants increases risk in indinavir treatment.
Gingivitis
Protease activity in gingival crevicular fluid from discrete periodontal sites in humans with periodontitis or gingivitis.
[The correlationship between the protease activity and the epithelial cells in the saliva from the patients with gingivitis or marginal periodontitis (author's transl)]
Glioblastoma
A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma.
Correction: Expression Analysis of All Protease Genes Reveals Cathepsin K to Be Overexpressed in Glioblastoma.
Expression analysis of all protease genes reveals cathepsin K to be overexpressed in glioblastoma.
HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.
Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).
Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme.
Overexpression and constitutive nuclear localization of cohesin protease Separase protein correlates with high incidence of relapse and reduced overall survival in glioblastoma multiforme.
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
Properties of cloned human glioblastoma cells. Release of a specific protease.
Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model.
Ubiquitin-specific protease 15 promotes tumor cell invasion and proliferation in glioblastoma.
Ubiquitin-specific protease 28 is overexpressed in human glioblastomas and contributes to glioma tumorigenicity by regulating MYC expression.
Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
Glioma
A protease storm cleaves a cell-cell adhesion molecule in cancer: multiple proteases converge to regulate PTPmu in glioma cells.
Anti-miRNA-23a Oligonucleotide Suppresses Glioma Cells Growth by Targeting Apoptotic Protease Activating Factor-1.
Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells.
In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas.
Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors.
Overexpression of Protease Serine 8 Inhibits Glioma Cell Proliferation, Migration, and Invasion via Suppressing the Akt/mTOR Signaling Pathway.
Protease activated receptor-1 and brain edema formation in glioma models.
Protease inhibitors generate cytotoxic fragments from Alzheimer amyloid protein precursor in cDNA-transfected glioma cells.
Protease Nexin-1 affects the migration and invasion of C6 glioma cells through the regulation of urokinase Plasminogen Activator and Matrix Metalloproteinase-9/2.
Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1.
Secretion of protease nexin-1 by C6 glioma cells is under the control of a heterotrimeric G protein, Go1.
The glioma cell-derived neurite promoting activity protein is functionally and immunologically related to human protease nexin-I.
Ubiquitin-specific protease 22 acts as an oncoprotein to maintain glioma malignancy through deubiquitinating B cell-specific Moloney murine leukemia virus integration site 1 for stabilization.
Ubiquitin-specific protease 22 promotes the proliferation, migration and invasion of glioma cells.
Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics.
Ubiquitin-specific protease 28 is overexpressed in human glioblastomas and contributes to glioma tumorigenicity by regulating MYC expression.
[The effects of protease inhibitors on glioma cells in culture]
Glomerulonephritis
Amelioration of immune complex-mediated glomerulonephritis by synthetic protease inhibitors.
[Effect of protease inhibitor on primary glomerulonephritis and the mechanism of the effect]
Glomerulonephritis, IGA
Bacterial protease for the treatment of IgA nephropathy.
Glomerulonephritis, Membranoproliferative
Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis.
Glucose Intolerance
Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance.
Effect of protease inhibitor therapy on glucose intolerance in pregnancy.
Impaired glucose tolerance and protease inhibitors.
Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.
Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency.
Glucosephosphate Dehydrogenase Deficiency
Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency.
Gonorrhea
Studies on gonococcus infection. XVII. IgA1-cleaving protease in vaginal washings from women with gonorrhea.
[Protease activity of gonococci in patients with various clinical forms of gonorrhea]
Graft vs Host Disease
Potential usefulness of protease inhibitor and chloroquine in the treatment of transfusion-associated graft-versus-host disease.
Granuloma
Collagenase, elastase, and nonspecific protease production by vigorous or immunomodulated liver granulomas and granuloma macrophages/eosinophils of S mansoni-infected mice.
Gynecomastia
Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones.
Head and Neck Neoplasms
Human papillomavirus infection in head and neck cancer: The role of the secretory leukocyte protease inhibitor.
Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: The Cancer Prevention Study II Nutrition Cohort.
Heart Diseases
Premature heart disease with protease inhibitors.
Protease inhibitors: emerging research explores possible link with heart disease. Experts say PI therapy remains essential for most.
Heart Failure
Ablation of the stress protease OMA1 protects against heart failure in mice.
HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.
Imaging of infarct healing predicts left ventricular remodeling and evolution of heart failure: focus on protease activity.
Oxidative post-translational modifications develop LONP1 dysfunction in pressure overload heart failure.
Protease activated receptor-2 contributes to heart failure.
Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure.
Hematologic Diseases
[Changes in the erythrocyte stroma protease in hematologic diseases]
[Protease inhibitor levels in diverse hematologic diseases]
Hematologic Neoplasms
The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K.
Hemoglobinuria
Protease inhibitors and haptoglobin for treatment of renal failure in paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
Protease inhibitors and haptoglobin for treatment of renal failure in paroxysmal nocturnal hemoglobinuria.
Hemophilia A
Haemophilia and the protease inhibitor in peanuts.
Monitoring but no drug-regimen changes advised for hemophilia patients taking protease inhibitors.
Plasma concentration of protein Z and protein Z-dependent protease inhibitor in patients with haemophilia A.
Successful use of protease inhibitors in HIV-infected haemophilia patients.
Hemophilia B
A moderate form of hemophilia B is caused by a novel mutation in the protease domain of factor IXVancouver.
Hemophilia B caused by five different nondeletion mutations in the protease domain of factor IX.
Region of factor IXa protease domain that interacts with factor VIIIa: analysis of select hemophilia B mutants.
Hemorrhagic Fever, Crimean
Crimean-Congo Hemorrhagic Fever Virus Suppresses Innate Immune Responses via a Ubiquitin and ISG15 Specific Protease.
Crimean-Congo hemorrhagic fever virus-encoded ovarian tumor (OTU) protease activity is dispensable for virus RNA polymerase function.
Inherent dynamics within the Crimean-Congo Hemorrhagic fever virus protease are localized to the same region as substrate interactions.
Structural analysis of a viral ovarian tumor domain protease from the crimean-congo hemorrhagic Fever virus in complex with covalently bonded ubiquitin.
Hepatitis
Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy.
Focus on hepatitis. HCV protease inhibitor does well in early clinical trial.
Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?
Hepatitis G virus encodes protease activities which can effect processing of the virus putative nonstructural proteins.
Hepatitis: Proof of concept for antiviral activity of protease inhibitor TMC435 monotherapy against multiple HCV genotypes.
Role of protease in mouse hepatitis virus-induced cell fusion. Studies with a cold-sensitive mutant isolated from a persistent infection.
Serum protease inhibitors in acute viral hepatitis.
Severe hepatitis in a HIV-positive subject under treatment with protease inhibitor.
Solid phase synthesis of peptide aldehyde protease inhibitors. Probing the proteolytic sites of hepatitis C virus polyprotein.
The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis.
The pathobiology of viral hepatitis and immunologic activation of the coagulation protease network.
[Clinical trial of protease inhibitor in the treatment of fulminant hepatitis]
[On the diagnostic and physiopathological significance of the changes in serum polypeptidase activity in epidemic hepatitis]
[Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
Hepatitis A
Protease digestion of hepatitis A virus: disparate effects on capsid proteins, antigenicity, and infectivity.
RNA interaction and cleavage of poly(C)-binding protein 2 by hepatitis A virus protease.
Hepatitis B
Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy.
Biosynthesis of hepatitis B virus e antigen: directed mutagenesis of the putative aspartyl protease site.
Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review.
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group.
Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection.
HIV Reverse Transcriptase and Protease Genes Variability Can Be a Biomarker Associated with HIV and Hepatitis B or C Coinfection.
Identification of a doubly spliced viral transcript joining the separated domains for putative protease and reverse transcriptase of hepatitis B virus.
Proteaselike sequence in hepatitis B virus core antigen is not required for e antigen generation and may not be part of an aspartic acid-type protease.
Hepatitis B, Chronic
Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor.
Hepatitis C
A comparative QM/MM study of the reaction mechanism of the Hepatitis C virus NS3/NS4A protease with the three main natural substrates NS5A/5B, NS4B/5A and NS4A/4B.
A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates.
A Highly Convergent and Efficient Synthesis of a Macrocyclic Hepatitis C Virus Protease Inhibitor BI 201302.
A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities.
A particular hepatitis C virus protease NS3 gene pattern in a patient not responding to interferon-ribavirin therapy.
A probabilistic peptide machine for predicting hepatitis C virus protease cleavage sites.
A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors.
A Synthesis of a Spirocyclic Macrocyclic Protease Inhibitor for the Treatment of Hepatitis C.
A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations.
A transient cell-based phenotype assay for hepatitis C NS3/4A protease: application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV.
A Twenty-Eight-Day Mechanistic Time Course Study in the Rhesus Monkey with Hepatitis C Virus Protease Inhibitor Biln 2061.
A1-2: Cost-Effectiveness of Interleukin 28B Genotype-Guided Protease Inhibitor Therapy in Treatment-Naive Patients with Hepatitis C Virus Genotype 2 or 3.
ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
Activity of purified hepatitis C virus protease NS3 on peptide substrates.
Activity-based proteome profiling of hepatoma cells during hepatitis C virus replication using protease substrate probes.
Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals.
Adapted J6/JFH1-based hepatitis C virus recombinants with genotype-specific NS4A show similar efficacy to lead protease inhibitors, interferon-alpha and a putative NS4A inhibitor.
An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver.
An update on the toxicological considerations for protease inhibitors used for hepatitis C infection.
Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model.
Analysis of the domain interactions between the protease and helicase of NS3 in dengue and hepatitis C virus.
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.
Arthralgias and cryoglobulinemia during protease inhibitor therapy in a patient infected with human immunodeficiency virus and hepatitis C virus.
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.
Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?
Biotransformation and mass balance of faldaprevir, a hepatitis C NS3/NS4 protease inhibitor in rats.
Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C.
Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C.
Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.
Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Characterization of clinical predictors of naturally occurring NS3/NS4A protease polymorphism in genotype 1 hepatitis C virus mono and HIV co-infected patients.
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients.
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients.
CHARACTERIZATION OF V36C, A NOVEL AMINO ACID SUBSTITUTION CONFERRING HEPATITIS C VIRUS (HCV) RESISTANCE TO TELAPREVIR, A POTENT PEPTIDOMIMETIC INHIBITOR OF HCV PROTEASE.
Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach.
Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort.
Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease.
Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors.
Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Nave Patients in Chile.
Cost of Adverse Drug Reactions (ADR) with Protease Inhibitors in the Treatment of Hepatitis C in the Health System of Extremadura (SES).
Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients.
Cost-effectiveness of IL28? genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection.
Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-?2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings.
Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Deep-Sequencing Analysis of the Gene Encoding the Hepatitis C Virus Nonstructural 3-4A Protease Confirms a Low Prevalence of Telaprevir-Resistant Variants at Baseline and the End of the REALIZE Study.
Dermatitis induced by first generation Hepatitis C virus protease inhibitors.
Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management.
Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit.
Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.
Determinants for Membrane Association of the Hepatitis C Virus NS2 Protease Domain.
Determinants of hepatitis C virus nonstructural protein 2 protease domain required for production of infectious virus.
Determination of simeprevir: A novel, hepatitis C protease inhibitor in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.
Development of a Practical, Asymmetric Synthesis of the Hepatitis C Virus Protease Inhibitor MK-5172.
Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
DNA immunization efficiently targets conserved functional domains of protease and ATPase/helicase of nonstructural 3 protein (NS3) of human hepatitis C virus.
Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.
Effect of Ritonavir-Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy.
Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.
Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil.
Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Nave Patients Infected with Hepatitis C Virus Genotype 1.
Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3.
Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.
ERAP1 allotypes impact the epitope repertoire of virus-specific CD8+ T cell responses in acute hepatitis C virus infection.
Erratum for Wire et al., Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease.
Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography.
Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors.
Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy.
Evolution of plasma hepatitis C virus load in patients coinfected by HIV and hepatitis C Virus started on a protease inhibitor-containing antiretroviral regimen, Agence Nationale de Recherches sur le SIDA CO8 APROCO-COPILOTE cohort.
Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3.
Expression and purification of hepatitis C virus protease from clinical samples.
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.
First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients.
Fragment-based development of HCV protease inhibitors for the treatment of hepatitis C.
From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals: self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials).
Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense.
Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity.
Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group.
Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.
Hepatitis C protease and polymerase inhibitors in development.
Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
Hepatitis C Virus Genotype 1-6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3.
Hepatitis C virus NS2 protease inhibits host cell antiviral response by inhibiting IKK? and TBK1 functions.
Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors.
Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease.
Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus.
Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.
Hepatitis C virus protease inhibitors: current progress and future challenges.
Hepatitis C virus protease inhibitors: patent highlight.
Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.
Hepatitis C virus resistance to protease inhibitors.
Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?
Hepatitis C, disease and its management: a cost-effectiveness analysis of the new generation oral protease inhibitors.
Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus.
High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy.
Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein.
Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients.
Identification of the protease domain in NS3 of hepatitis C virus.
Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C.
Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients.
Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.
Impact of protease inhibitors on intrahepatic hepatitis C virus viral load.
Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.
In trans interaction of hepatitis C virus helicase domains mediates protease activity critical for internal NS3 cleavage and cell transformation.
In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.
In vitro activity of hepatitis C virus protease NS3 purified from recombinant Baculovirus-infected Sf9 cells.
In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats.
In vitro inhibition of Hepatitis C virus protease and antioxidant by flavonoid glycosides from the Saudi costal plant Sarcocornia fruticosa.
Inhibition of both protease and helicase activities of hepatitis C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp.
Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor.
Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.
Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.
Inhibitors of hepatitis C virus NS3.4A protease: an overdue line of therapy.
Inhibitory effects of antrodins A-E from Antrodia cinnamomea and their metabolites on hepatitis C virus protease.
Inhibitory effects of sudanese medicinal plant extracts on hepatitis C virus (HCV) protease.
Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation.
Internal cleavage of hepatitis C virus NS3 protein is dependent on the activity of NS34A protease.
Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease.
Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034.
Limited effect on NS3-NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease.
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Mass Balance and Metabolite Profiling of Steady-State Faldaprevir, a Hepatitis C Virus NS3/4 Protease Inhibitor, in Healthy Male Subjects.
Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors.
Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.
Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro.
MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.
Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor.
Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition.
Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.
Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naïve patients.
Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors.
Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection.
Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase.
Novel hepatitis C virus protease inhibitors: thiazolidine derivatives.
Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection.
NS2 proteins of GB virus B and hepatitis C virus share common protease activities and membrane topologies.
NS3.4A protease as a target for interfering with hepatitis C virus replication.
Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.
Pan-NS3 protease inhibitors of hepatitis C virus based on an R
PCR-Based In Vitro Synthesis of Hepatitis C Virus NS3 Protease for Rapid Phenotypic Resistance Testing of Protease Inhibitors.
Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone.
Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors.
Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.
Polymorphisms associated with resistance to protease inhibitors in nave patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of a hepatitis C virus NS3-NS4A complex isolated from transfected COS cells.
Polypharmacy and Comorbidity Are Associated with a Lower Early Virologic Response in Hepatitis C Patients Treated with First Generation Protease Inhibitor Triple Therapy: A Preliminary Analysis.
Predicting hepatitis C virus protease cleavage sites using generalized linear indicator regression models.
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors.
Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba.
Prevalence of hepatitis C virus mutants resistant to protease inhibitors among Polish HCV genotype 1-infected patients.
Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in So Paulo state.
Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection.
Prisoners treated for hepatitis C with protease inhibitor, New York, USA, 2012.
Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
Protease and polymerase inhibitors for the treatment of hepatitis C.
Protease inhibitor therapy for hepatitis C virus-infection.
Protease inhibitor therapy post-liver transplantation in the treatment of hepatitis C virus infection.
Protease inhibitor-based therapy for hepatitis C virus infection-why wait?
Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.
Protease inhibitors block multiple functions of the NS3/4A protease-helicase during the hepatitis C virus life cycle.
Protease inhibitors for hepatitis C: economic implications.
Protease inhibitors for the treatment of hepatitis C virus infection.
Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.
Protease inhibitors in hepatitis C: from chronic disease to cure.
Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.
Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons.
Rapid emergence of protease inhibitor resistance in hepatitis C virus.
Re: Pearlman and Ehleben - Hepatitis C Genotype 1 Virus with Low Viral Load and Rapid Virologic Response to Peginterferon/Ribavirin Obviates a Protease Inhibitor.
Re: Pearlman and ehleben - hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.
Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials.
Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.
Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease.
Reconstitution of hepatitis C virus protease activities in yeast.
Relation between viral fitness and immune escape within the hepatitis C virus protease.
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
Resistance to hepatitis C virus protease inhibitors.
Restoration of the Activated Rig-I Pathway in Hepatitis C Virus (HCV) Replicon Cells by HCV Protease, Polymerase, and NS5A Inhibitors In Vitro at Clinically Relevant Concentrations.
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
Safety and Efficacy of Protease Inhibitors to Treat Hepatitis C After Liver Transplantation, a Multicenter Experience.
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
SCREENING OF PROTEASE INHIBITORS RESISTANCE MUTATIONS IN HEPATITIS C VIRUS ISOLATES INFECTING ROMANIAN PATIENTS UNEXPOSED TO TRIPLE THERAPY.
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
Septic Bursitis, a Potential Complication of Protease Inhibitor Use in Hepatitis C Virus.
Serpin mechanism of hepatitis C virus nonstructural 3 (NS3) protease inhibition: induced fit as a mechanism for narrow specificity.
Similarities between Human Immunodeficiency Virus Type 1 and Hepatitis C Virus Genetic and Phenotypic Protease Quasispecies Diversity.
Simultaneous quantification of simeprevir sodium: A hepatitis C protease inhibitor in binary and ternary mixtures with sofosbuvir and/or ledipasvir utilizing direct and H-point standard addition strategies.
Solid phase synthesis of peptide aldehyde protease inhibitors. Probing the proteolytic sites of hepatitis C virus polyprotein.
Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.
Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
Sustained virologic response after 6 weeks of therapy with a first-generation hepatitis C virus protease inhibitor.
Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.
Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease.
Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase.
Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.
Telaprevir: an oral protease inhibitor for hepatitis C virus infection.
Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual.
Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase).
The design of potent, non-peptidic inhibitors of hepatitis C protease.
The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors.
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities.
The potency-insolubility conundrum in pharmaceuticals: Mechanism and solution for hepatitis C protease inhibitors.
The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
The protease domain increases the translocation stepping efficiency of the hepatitis C virus NS3-4A helicase.
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
The RNA-unwinding activity of hepatitis C virus non-structural protein 3 (NS3) is positively modulated by its protease domain.
The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors.
The role of P-glycoprotein in the pharmacokinetics and tissue distribution of a hepatitis C virus protease inhibitor.
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 nave patients.
The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors.
Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.
Treatment of hepatitis C 2010: a focus on protease inhibitors.
Treatment of hepatitis C with the earliest protease inhibitor-based therapy.
Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women.
Trends in hepatitis C virus infection therapy: protease inhibitors a step forward in the era of direct acting antivirals.
Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes.
Two Years' Persistence of Naturally Present Substitution R155K Within Hepatitis C Virus NS3 Protease in the Absence of Protease Inhibitor-based Therapy.
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors.
Withdrawal: Hepatitis C virus NS5A and subgenomic replicon activate NF- ? B via tyrosine phosphorylation of I ? B ? and its degradation by calpain protease.
[Clarifying the crystal structure of hepatitis C virus NS3/NS4A protease complex--basics for the development of specific HCV protease inhibitors?]
[Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors.]
[Protease inhibitors against hepatitis C]
[Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
Hepatitis C, Chronic
Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection.
Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C (September).
Chronic hepatitis C: treat or wait? A prospective study on reasons for treatment or nontreatment in the era of first-generation protease inhibitors.
Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
Correction: Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.
Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature.
Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C.
Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.
Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
IFN-? gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors.
Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.
Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir.
Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in denmark: identification of viral resistance mutations.
Nationwide prediction of future expenditure for protease inhibitors in chronic hepatitis C.
Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection.
Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24.
Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Protease inhibitor-based triple therapy in chronic hepatitis C: Guidelines by the French association for the study of the Liver.
Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C.
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.
Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.
Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients.
Protease inhibitors: Silver bullets for chronic hepatitis C infection?
Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease.
Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors.
Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.
Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy.
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.
Safety aspects of protease inhibitors for chronic hepatitis C: Adverse events and drug-to-drug interactions.
The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir.
Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation.
Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.
Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?
Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian Association for the Study of the Liver (AISF).
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients.
Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection.
Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C.
[Attempts to treat chronic hepatitis C with HCV protease inhibitor].
[Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis].
[Protease inhibitors in the treatment of chronic hepatitis C.]
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
[Treatment of chronic hepatitis C with protease inhibitors: dawn of a new era].
Hepatitis, Chronic
Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Protease inhibitors for treatment of chronic hepatitis C--a new target for the magic bullet identified.
Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
[Resistance to protease inhibitors and efficiency of antiviral therapy in patients with chronic hepatitis C].
[Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
Herpes Simplex
Activation of the herpes simplex virus type 1 protease.
Alterations in catalytic activity and virus maturation produced by mutation of the conserved histidine residues of herpes simplex virus type 1 protease.
Autocatalytic Activity of the Ubiquitin-Specific Protease Domain of Herpes Simplex Virus 1 VP1-2.
Autoproteolysis of herpes simplex virus type 1 protease releases an active catalytic domain found in intermediate capsid particles.
Characterization of the protease and other products of amino-terminus-proximal cleavage of the herpes simplex virus 1 UL26 protein.
Differentiation of multiple domains in the herpes simplex virus 1 protease encoded by the UL26 gene.
Dimerization and activation of the herpes simplex virus type 1 protease.
Evidence for controlled incorporation of herpes simplex virus type 1 UL26 protease into capsids.
Expression of natural and synthetic genes encoding herpes simplex virus 1 protease in Escherichia coli and purification of the protein.
Herpes Simplex Virus 1 Ubiquitin-Specific Protease UL36 Abrogates NF-?B Activation in DNA Sensing Signal Pathway.
Herpes Simplex Virus 1 Ubiquitin-Specific Protease UL36 Inhibits Beta Interferon Production by Deubiquitinating TRAF3.
Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism.
Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.
Herpes simplex virus type 1 protease expressed in Escherichia coli exhibits autoprocessing and specific cleavage of the ICP35 assembly protein.
Identification of the herpes simplex virus-1 protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products.
Identification of the serine residue at the active site of the herpes simplex virus type 1 protease.
Impact of the Interaction between Herpes Simplex Virus Type 1 Regulatory Protein ICP0 and Ubiquitin-Specific Protease USP7 on Activation of Adeno-Associated Virus Type 2 rep Gene Expression.
In vitro activity of the herpes simplex virus type 1 protease with peptide substrates.
Investigation of the specificity of the herpes simplex virus type 1 protease by point mutagenesis of the autoproteolysis sites.
Na, an autoproteolytic product of the herpes simplex virus type 1 protease, can functionally substitute for the assembly protein ICP35.
Nucleotide sequence of the herpes simplex virus type 2 gene encoding the protease and capsid protein ICP35.
Overexpression of the ubiquitin-specific protease 7 resulting from transfection or mutations in the ICP0 binding site accelerates rather than depresses herpes simplex virus 1 gene expression.
Phenotype of the herpes simplex virus type 1 protease substrate ICP35 mutant virus.
Production of recombinant herpes simplex virus protease in 10-L stirred vessels using a baculovirus-insect cell expression system.
Purification of active herpes simplex virus-1 protease expressed in Escherichia coli.
Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7.
Release of the catalytic domain N(o) from the herpes simplex virus type 1 protease is required for viral growth.
Release of the herpes simplex virus 1 protease by self cleavage is required for proper conformation of the portal vertex.
Retraction. Tsg101 interacts with herpes simplex virus 1 VP1/2 and is a substrate of VP1/2 ubiquitin-specific protease domain activity.
Separate functional domains of the herpes simplex virus type 1 protease: evidence for cleavage inside capsids.
Stimulation of the herpes simplex virus type I protease by antichaeotrophic salts.
Structural Characterization of Interaction between Human Ubiquitin-specific Protease 7 and Immediate-Early Protein ICP0 of Herpes Simplex Virus-1.
The ability of herpes simplex virus type 1 immediate-early protein Vmw110 to bind to a ubiquitin-specific protease contributes to its roles in the activation of gene expression and stimulation of virus replication.
The C-terminal 25 amino acids of the protease and its substrate ICP35 of herpes simplex virus type 1 are involved in the formation of sealed capsids.
The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate.
The major transcriptional regulatory protein of herpes simplex virus type 1 includes a protease resistant DNA binding domain.
The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth.
Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease activated receptor 2 cofactors that enhance infection.
Tsg101 interacts with herpes simplex virus 1 VP1/2 and is a substrate of VP1/2 ubiquitin-specific protease domain activity.
Ubiquitin-specific protease 9X in host cells interacts with herpes simplex virus 1 ICP0.
Herpes Zoster
Alterations in mast cell proteinases and protease inhibitors in the progress of cutaneous herpes zoster infection.
Effects of protease inhibitors on adenylate cyclase activation and aldosterone production in rat adrenal zona glomerulosa cells.
Evidence for the involvement of a species-specific embryonic protease in zona escape of hamster blastocysts.
Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors.
High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors.
Ovastacin, a cortical granule protease, cleaves ZP2 in the zona pellucida to prevent polyspermy.
Protease activity involvement in the passage of mammalian sperm through the zona pellucida.
Hirschsprung Disease
Effects of potato-derived protease inhibitors on perianal dermatitis after colon resection for long-segment Hirschsprung's disease.
Histoplasmosis
Protease inhibitors and azolic antifungals in HIV patients with histoplasmosis: a clinical pharmacokinetics perspective.
HIV Infections
A combination of nucleoside analogues and a protease inhibitor reduces HIV-1 RNA levels in semen: implications for sexual transmission of HIV infection.
A phase I/II study of the protease inhibitor indinavir in children with HIV infection.
A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence.
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.
Antiretroviral Drug Guidelines for the Treatment of HIV Infection: Should Protease Inhibitors Always be Included in the Initial Regimen or Not?
Apoptosis induced by HIV infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas(CD95) antagonist.
Atazanavir: a new protease inhibitor to treat HIV infection.
Bestatin-mediated inhibition of leucine aminopeptidase may hinder HIV infection.
Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure.
Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection.
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.
Development of inhibitors of reverse transcriptase and protease as therapeutics against HIV infection.
Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial.
Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an Urban Veterans Affairs Medical Center.
Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors.
Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?
Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
Endoplasmic reticulum aminopeptidase 2 (ERAP2) haplotypes play a role in modulating susceptibility to HIV infection.
Evaluation of simplified protease inhibitor dosing regimens for the treatment of HIV infection.
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
FDA approves new protease inhibitor for HIV infection.
Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro.
HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic.
Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.
Interleukin-1 beta converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection.
Is the atherosclerotic process accentuated under conditions of HIV infection, antiretroviral therapy, and protease inhibitor exposure? Meta-analysis of the markers of arterial structure and function.
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.
Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.
Protease activation during HIV infection in a CD4-positive cell line.
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection.
Protease inhibitor monotherapy for long-term management of HIV infection.
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.
Protease inhibitor therapy for HIV infection: the effect on HIV-associated nephrotic syndrome.
Protease inhibitor therapy improves protein catabolism in prepubertal children with HIV infection.
Protease inhibitor therapy in children with perinatally acquired HIV infection.
Protease inhibitor-associated hyperglycemia in Mexican patients with HIV infection.
Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.
Protease inhibitors as immunomodulatory drugs for HIV infection.
Protease inhibitors for HIV infection.
Protease inhibitors in HIV infection. Lipodystrophy may be a consequence of prolonged survival.
Protease inhibitors show promise in HIV infection.
Recent patents and emerging therapeutics for HIV infections: a focus on protease inhibitors.
Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
Reversal of abnormalities of neutrophil adhesion molecule expression in HIV infection following protease inhibitor therapy.
Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study.
Salivary secretory leukocyte protease inhibitor increases in HIV infection.
Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients.
Simultaneous use of two protease inhibitors in HIV infection.
Stability analysis for HIV infection delay model with protease inhibitor.
The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
The role of combinations of HIV protease inhibitors in the management of persons with HIV infection.
The role of protease inhibitor therapy in children with HIV infection.
Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.
Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.
Use of Boosted Protease Inhibitors Reduces Kaposi Sarcoma Incidence Among Male Veterans With HIV Infection.
Visceral obesity, hypertriglyceridemia and hypercortisolism in a boy with perinatally acquired HIV infection receiving protease inhibitor-containing antiviral treatment.
[Clinical studies on the use of protease inhibitors in HIV infection. Answers and questions]
[Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released]
[Factors predictive of early virologic response after a first treatment with an protease inhibitor in the course of HIV infection]
[HIV infection, quality of life and protease inhibitors]
[HIV protease inhibitors (new possibilities in the treatment of HIV infection and AIDS)]
[Hyperlipidemia in patients with HIV infection treated with protease inhibitors]
[Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy]
[Pharma-clinics how I treat ... an HIV infection. IV. Protease inhibitors]
[Predictive factors of virologic response to antiretroviral treatment with a protease inhibitor in HIV infection]
[Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS]
[Protease inhibitors in HIV infection]
[Protease inhibitors--new preparations for treatment of HIV infections]
[The lipodystrophy syndrome and protease inhibitor therapy in HIV infection]
[Treatment of HIV infection in clinical practice. Wide-range genotypic resistance to all nucleoside analogues and protease inhibitors, and severe intolerance to all non-nucleoside inhibitors of inverse transcriptase]
[Treatment of HIV infections and AIDS with protease inhibitor and two nucleoside analogs]
HIV-Associated Lipodystrophy Syndrome
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.
Hodgkin Disease
Characterization of the interleukin-1beta-converting enzyme/ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease: lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease.
Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma.
Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.
Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor.
Immunohistochemical analysis of interleukin-1beta-converting enzyme/Ced-3 family protease, CPP32/Yama/Caspase-3, in Hodgkin's disease.
Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.
Protease receptors in Hodgkin's disease: expression of the factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells.
Huntington Disease
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: mitochondrial dysfunction and neurodegeneration.
Hyperalgesia
A low dose of fermented soy germ alleviates gut barrier injury, hyperalgesia and faecal protease activity in a rat model of inflammatory bowel disease.
Decreased concentration of protease inhibitors: possible contributors to allodynia and hyperalgesia in women with vestibulodynia.
Transient receptor potential vanilloid 4 mediates protease activated receptor 2-induced sensitization of colonic afferent nerves and visceral hyperalgesia.
Hypercholesterolemia
Association of Hypercholesterolemia Incidence With Antiretroviral Treatment, Including Protease Inhibitors, Among Perinatally HIV-Infected Children.
Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors.
The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727 McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase Subtilisin/Kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012. [Epub ahead of print].
Hyperglycemia
A review of protease inhibitor-induced hyperglycemia.
Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.
Human obesity and thinness, hyperlipidemia, hyperglycemia, and insulin resistance associated with HIV1 protease inhibitors. Prevention by alternating several antiproteases in short sequences.
Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population.
Hyperglycemia associated with protease inhibitors in HIV-1-infected patients.
Hyperglycemia potentiates carbonyl stress-induced apoptosis in naïve PC-12 cells: relationship to cellular redox and activator protease factor-1 expression.
Protease inhibitor-associated hyperglycemia in Mexican patients with HIV infection.
[Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released]
[Lipodystrophy and hyperglycemia produced by protease inhibitors]
Hyperinsulinism
Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use.
Hyperlipidemias
Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.
HIV protease inhibitors and hyperlipidemia: a fatty acid connection.
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.
Human obesity and thinness, hyperlipidemia, hyperglycemia, and insulin resistance associated with HIV1 protease inhibitors. Prevention by alternating several antiproteases in short sequences.
Hyperlipidemia and inhibitors of HIV protease.
Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.
Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.
Hyperlipidemia associated with protease inhibitor therapy.
Hyperlipidemia associated with the use of protease inhibitors.
Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases.
Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.
Intervention for hyperlipidemia associated with protease inhibitors.
Lipemia retinalis as a presenting feature of hypertriglyceridemia associated with protease inhibitors in human immunodeficiency virus-infected patients.
Lipemia retinalis in acquired immunodeficiency syndrome treated with protease inhibitors.
Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
Management of protease inhibitor-associated hyperlipidemia.
Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report.
Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia.
[Hyperlipidemia in patients with HIV infection treated with protease inhibitors]
Hyperprolactinemia
Galactorrhoea, hyperprolactinaemia, and protease inhibitors.
Hypersensitivity
A protease inhibitor against acute stress-induced visceral hypersensitivity and paracellular permeability in rats.
Allergic reactions, including asthma, to the pineapple protease bromelain following occupational exposure.
Evaluation of colonoscopic allergen provocation as a diagnostic tool in dogs with proven food hypersensitivity reactions.
Hypersensitivity reactions during antiretroviral regimens with protease inhibitors.
Inhibition of the formation of hypersensitivity pyrogen from delayed hypersensitive cell extract by protease inhibitors in vitro.
Lysosomal proteases and protease inhibitors in nasal allergy and non-atopic sinusitis.
Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
Protease Activated Receptor-2 Induces Immune Activation and Visceral Hypersensitivity in Post-infectious Irritable Bowel Syndrome Mice.
The significance of nasal protease inhibitor concentrations in house dust allergy.
[A case of allergy to protease inhibitors]
Hypersensitivity, Delayed
A high-molecular-weight trypsinlike protease in the skin sites of delayed hypersensitivity in guinea pigs.
The chemical mediation of delayed hypersensitivity skin reactions. IV. Activation of chemotactic factor precursor by a trypsin-like protease in guinea pig plasma.
Hypertension
Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.
Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension.
Effect of short-term pancreatico-biliary duct obstruction with intraductal hypertension on subcellular organelle fragility and pancreatic adenylate energy metabolism in rats: protective effect of a new protease inhibitor, E-3123.
Gene Variation of Endoplasmic Reticulum Aminopeptidases 1 and 2, and Risk of Blood Pressure Progression and Incident Hypertension among 17,255 Initially Healthy Women.
HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension.
Reduced activity of the hypertension-associated Lys528Arg mutant of human adipocyte-derived leucine aminopeptidase (A-LAP)/ER-aminopeptidase-1.
Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor.
Hypertension, Pulmonary
Effects of HIV Protease Inhibitors on Progression of Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension in Rats.
HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension.
Sildenafil Plasma Concentrations in Two HIV Patients with Pulmonary Hypertension Treated with Ritonavir-Boosted Protease Inhibitors.
Hypertriglyceridemia
Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan.
Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients.
Globin digest, acidic protease hydrolysate, inhibits dietary hypertriglyceridemia and Val-Val-Tyr-Pro, one of its constituents, possesses most superior effect.
Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors.
Lipemia retinalis as a presenting feature of hypertriglyceridemia associated with protease inhibitors in human immunodeficiency virus-infected patients.
Plasmapheresis in the treatment of an acute pancreatitis due to protease inhibitor-induced hypertriglyceridemia.
Visceral obesity, hypertriglyceridemia and hypercortisolism in a boy with perinatally acquired HIV infection receiving protease inhibitor-containing antiviral treatment.
[Protease inhibitor-associated hypertriglyceridemia and diabetes mellitus in HIV-infected patients]
Hypogonadism
Novel mutations in testis-specific ubiquitin protease 26 gene may cause male infertility and hypogonadism.
Hypokinesia
Digestive tract of rats after hypokinesia and hypergravitation.
Hypotension
ERp44 Exerts Redox-Dependent Control of Blood Pressure at the ER.
Hypothyroidism
Protease inhibitor-associated bone mineral density loss is related to hypothyroidism and related bone turnover acceleration.
Protease inhibitors in sera as possible indicators of familial hypothyroidism.
Hypotrichosis
Mutation G827R in Matriptase Causing Autosomal Recessive Ichthyosis with Hypotrichosis Yields an Inactive Protease.
Ichthyosis
Cytotoxic effects of protease inhibitors on human cells. 1. High sensitivity of xeroderma pigmentosum cells to antipain.
Mutation G827R in Matriptase Causing Autosomal Recessive Ichthyosis with Hypotrichosis Yields an Inactive Protease.
Mutations in CSTA, encoding Cystatin A, underlie exfoliative ichthyosis and reveal a role for this protease inhibitor in cell-cell adhesion.
Ichthyosis, Lamellar
Harlequin ichthyosis: ABCA12 mutations underlie defective lipid transport, reduced protease regulation and skin-barrier dysfunction.
Idiopathic Pulmonary Fibrosis
Increased expression of protease nexin-1 in fibroblasts during idiopathic pulmonary fibrosis regulates thrombin activity and fibronectin expression.
Non-invasive Imaging of Idiopathic Pulmonary Fibrosis Using Cathepsin Protease Probes.
Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis.
Immune Reconstitution Inflammatory Syndrome
Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors.
Immune System Diseases
Genetic Variants in ERAP1 and ERAP2 Associated With Immune-Mediated Diseases Influence Protein Expression and the Isoform Profile.
Infarction, Middle Cerebral Artery
Expression of myelencephalon-specific protease in transient middle cerebral artery occlusion model of rat brain.
The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis.
Infection
A functional ubiquitin-specific protease embedded in the large tegument protein (ORF64) of murine gammaherpesvirus 68 is active during the course of infection.
A gammaherpesvirus ubiquitin-specific protease is involved in the establishment of murine gammaherpesvirus 68 infection.
A Novel Fungal Protease Expressed in Endophytic Infection of Poa Species.
A Protease Inhibitor with Induction Therapy with Natural Interferon-? in Patients with HCV Genotype 1b Infection.
A secretory leukocyte protease inhibitor variant with improved activity against lung infection.
A signaling protease required for melanization in Drosophila affects resistance and tolerance of infections.
Activation of plasminogen activator inhibitor implicates protease InhA in the acute-phase response to Bacillus anthracis infection.
Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
Adrenal Enzyme Impairment in Neonates and Adolescents Treated with Ritonavir and Protease Inhibitors for HIV Exposure or Infection.
Alterations in mast cell proteinases and protease inhibitors in the progress of cutaneous herpes zoster infection.
An extracellular protease from Brevibacillus laterosporus G4 without parasporal crystals can serve as a pathogenic factor in infection of nematodes.
An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.
An update on the toxicological considerations for protease inhibitors used for hepatitis C infection.
Analysis of protease activity in Aspergillus flavus and A. parasiticus on peanut seed infection and aflatoxin contamination
Antibody to the Dirofilaria immitis aspartyl protease inhibitor homologue is a diagnostic marker for feline heartworm infections.
Antigenicity of a filarial protease from Setaria digitata in Wuchereria bancrofti infection.
Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3.
Assessment of protease (elastase) as a Pseudomonas aeruginosa virulence factor in experimental mouse burn infection.
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.
Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection.
Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
Bovine viral diarrhea virus: prevention of persistent fetal infection by a combination of two mutations affecting Erns RNase and Npro protease.
Catch-and-release probes applied to semi-intact cells reveal ubiquitin-specific protease expression in Chlamydia trachomatis infection.
Circulating levels and ex vivo production of beta-chemokines, interferon gamma, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: the effect of protease inhibitor therapy.
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?
Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.
Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.
Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection.
Construction of a novel SHIV having an HIV-1-derived protease gene and its infection to rhesus macaques: a useful tool for in vivo efficacy tests of protease inhibitors.
Contribution of Aspartic Proteases in Candida Virulence. Protease Inhibitors against Candida Infections.
Cost-effectiveness of IL28? genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection.
Could targeting secretory leukocyte protease inhibitor be an effective therapeutic option to prevent infections in acute liver failure?
Deletion of the SNP1 trypsin protease from Stagonospora nodorum reveals another major protease expressed during infection.
Diagnosis of Corynebacterium pyogenes infection in pigs by immunodiffusion test with protease antigen.
Diagnosis of Fasciola gigantica infection using a monoclonal antibody-based sandwich ELISA for detection of circulating cathepsin B3 protease.
Dietary protease can alleviate negative effects of a coccidiosis infection on production performance in broiler chickens
Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects.
Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.
Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil.
Effectiveness of protease inhibitor/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of HIV-1 infection in sub-Saharan Africa: systematic review and meta-analysis.
Effects of immunization of horses with common antigen (OEP), protease toxoid, and elastase toxoid on corneal ulceration due to Pseudomonas aeruginosa infection.
Effects of zinc sulfate on Pseudomonas aeruginosa infections and protease in rabbit corneas.
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro.
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
Emtricitabine/Tenofovir Disoproxil Fumarate: In Combination with a Protease Inhibitor in HIV-1 Infection.
Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors.
ERAP1 allotypes impact the epitope repertoire of virus-specific CD8+ T cell responses in acute hepatitis C virus infection.
Evaluation of genotypic and phenotypic protease virulence tests for Dichelobacter nodosus infection in sheep.
Evaluation of immunoglobulin A1 (IgA1) protease and IgA1 protease-inhibitory activity in human female genital infection with Neisseria gonorrhoeae.
Evaluation of three disk tests for identification of enterococci, leuconostocs, and pediococci.
Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: effect of treatment with protease inhibitors.
Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: extracellular protease and elastase as in vivo virulence factors.
Experimental studies of the pathogenesis of infections owing to Pseudomonas aeruginosa: elastase, an IgG protease.
Expression and translocation of chlamydial protease during acute and persistent infection of the epithelial HEp-2 cells with Chlamydophila (Chlamydia) pneumoniae.
Expression of secretory leukocyte protease inhibitor and elafin in human fallopian tube and in an in-vitro model of Chlamydia trachomatis infection.
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection.
Genetic diversity at endoplasmic reticulum aminopeptidases is maintained by balancing selection and is associated with natural resistance to HIV-1 infection.
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
Helicobacter pylori Infection, but not Low-Dose Aspirin, Results in a Local Reduction of the Secretory Leukocyte Protease Inhibitor in Gastroduodenal Mucosa.
Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.
High protease activity of Chryseobacterium indologenes isolates associated with invasive infection.
High Risk of Infection During Triple Therapy with First-Generation Protease Inhibitors: A Nationwide Cohort Study.
HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance: Which Salvage Regimen?
Host defense responses to infection by Mycobacterium tuberculosis. Induction of IRF-1 and a serine protease inhibitor.
HtrA, a Temperature- and Stationary Phase-Activated Protease Involved in Maturation of a Key Microbial Virulence Determinant, Facilitates Borrelia burgdorferi Infection in Mammalian Hosts.
Human mucus protease inhibitor in airway fluids is a potential defensive compound against infection with influenza A and Sendai viruses.
Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection.
Identification of protease and rpoN-associated genes of uropathogenic Proteus mirabilis by negative selection in a mouse model of ascending urinary tract infection.
Immunization of hamsters against Clostridium difficile infection using the Cwp84 protease as an antigen.
Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection.
Impact of protease polymorphisms and viral fitness on human immunodeficiency virus (HIV) type 1 viremia in untreated HIV-1 infection.
In vivo bacterial protease production during Pseudomonas aeruginosa corneal infection.
In vivo characterization of host and bacterial protease expression during Pseudomonas aeruginosa corneal infections in naive and immunized mice.
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
Interleukin-1 beta converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection.
Involvement of the GP63 protease in infection of Trichomonas vaginalis.
Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections.
Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Molecular mechanism of complex infection by bacteria and virus analyzed by a model using serratial protease and influenza virus in mice.
Mutations in reovirus outer-capsid protein sigma3 selected during persistent infections of L cells confer resistance to protease inhibitor E64.
Neutrophil elastase and secretory leukocyte protease inhibitor in prelabor rupture of membranes, parturition and intra-amniotic infection.
New sensitive markers for the detection of experimental ascending pyelonephritis.
No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001.
Novel roles of protease inhibitors in infection and inflammation.
Null Mutations of Group A Streptococcus Orphan Kinase RocA: Selection in Mouse Infection and Comparison with CovS Mutations in Alteration of In Vitro and In Vivo Protease SpeB Expression and Virulence.
Parvovirus Capsid Structures Required for Infection: Mutations Controlling Receptor Recognition and Protease Cleavages.
Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease.
Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates.
Protease activity and phytocystatin expression in Arabidopsis thaliana upon Heterodera schachtii infection.
Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection.
Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections.
Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.
Protease inhibitors in Bombyx mori silk might participate in protecting the pupating larva from microbial infection.
Protease production by microorganisms associated with reproductive tract infection.
Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection.
Reaching the melting point: Degradative enzymes and protease inhibitors involved in baculovirus infection and dissemination.
Reassessing the role of the secreted protease CPAF in Chlamydia trachomatis infection through genetic approaches.
Relationships between protease activity, host blood and infection rates in Glossina morsitans sspp. infected with Trypanosoma congolense, T. brucei and T. simiae.
Resistance to protease inhibitors in a model of HIV-1 infection with impulsive drug effects.
Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor.
Rickettsia conorii infection stimulates the expression of ISG15 and ISG15 protease UBP43 in human microvascular endothelial cells.
Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.
Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa.
Role of protease in mouse hepatitis virus-induced cell fusion. Studies with a cold-sensitive mutant isolated from a persistent infection.
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.
Salmonella enterica Serovar Typhimurium HtrA: regulation of expression and role of the chaperone and protease activities during infection.
Saquinavir Inhibits Early Events Associated with Establishment of HIV-1 Infection: Potential Role for Protease Inhibitors in Prevention.
Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection.
Secretory leukocyte protease inhibitor expression in various types of gastritis: a specific role of Helicobacter pylori infection.
Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers.
Secretory leukocyte protease inhibitor: inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein.
Selection of Clinically-relevant Protease Inhibitor Resistant Viruses Using the Genotype 2a HCV Infection System.
Serum derived protease inhibitors and leucocyte elastase in sputum and the effect of infection.
Small-Molecule Inhibitors of Lethal Factor Protease Activity Protect against Anthrax Infection.
Specific in vitro cleavage of Mason-Pfizer monkey virus capsid protein: evidence for a potential role of retroviral protease in early stages of infection.
Specific protease activity indicates the degree of Pseudomonas aeruginosa infection in chronic infected wounds.
Studies on gonococcus infection. XVI. Purification of Neisseria gonorrhoeae immunoglobulin A1 protease.
Studies on gonococcus infection. XVII. IgA1-cleaving protease in vaginal washings from women with gonorrhea.
The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis.
The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection.
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.
The effect of infection with tobacco-mosaic virus on the levels of nitrogen, phosphorus, protease, and pectase in tobacco leaves and on their response to fertilizers.
The effect of treatment with a protease inhibitor on mycobacterial infection.
The electrophoretic mobility of alpha 1-antitrypsin in sputum and its relationship to protease inhibitory capacity, leucocyte elastase concentrations and acute respiratory infection.
The ERAP gene is associated with HCV chronic infection in a Chinese Han population.
The human mucus protease inhibitor and its mutants are novel defensive compounds against infection with influenza A and Sendai viruses.
THE PROTEASE LOCUS of FRANCISELLA TULARENSIS LVS IS REQUIRED FOR STRESS TOLERANCE AND INFECTION OF MAMMALIAN HOST.
The Pseudomonas aeruginosa periplasmic protease CtpA can affect systems that impact its ability to mount both acute and chronic infections.
The role of endoplasmic reticulum-associated aminopeptidase 1 in immunity to infection and in cross-presentation.
The Role of Vibrio cholerae Haemagglutinin Protease (HAP) in Extra-Intestinal Infection.
Therapeutic advances: protease inhibitors for the treatment of HIV-1 infection.
Therapeutic effect of immunization with OEP, protease toxoid and elastase toxoid on corneal ulcers in mice due to Pseudomonas aeruginosa infection.
Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with a half-sized secretory leukocyte protease inhibitor or the nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection in mice.
Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection.
Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease activated receptor 2 cofactors that enhance infection.
Towards tricking a pathogen's protease into fighting infection: the 3D structure of a stable circularly permuted onconase variant cleavedby HIV-1 protease.
Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection.
Use of recombinase-based in vivo expression technology to characterize Enterococcus faecalis gene expression during infection identifies in vivo-expressed antisense RNAs and implicates the protease Eep in pathogenesis.
[Effects of half-sized secretory leukocyte protease inhibitor and Chinese traditional medicines, yokuinin and mao-bushi-saishin-to, on therapeutic efficacies of benzoxazinorifamycin KRM-1648 against Mycobacterium avium complex infection induced in mice]
[Effects of secretory leukocyte protease inhibitor on the production of some cytokines and nitric oxide by murine peritoneal macrophages in response to lipopolysaccharide stimulation and M. avium complex infection]
[HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV].
[Influence of plasmid pR50 controlling bacterial protease activity on Salmonella experimental infection]
[Recent development of novel reverse transcriptase inhibitors and protease inhibitors against HIV-1 infection]
[The protease inhibitor gabexate mesilate in experimentally-induced acute pancreatitis with early gram-negative infection in the Göttingen minipig: therapeutic efficacy and effects on blood coagulation and fibrinolysis]
Infertility
Acrosin antibodies and infertility. I. Detection of antibodies towards proacrosin/acrosin in women consulting for infertility and evaluation of their effects upon the sperm protease activities.
Binding of human secretory leukocyte protease inhibitor in uterine cervical mucus to immunoglobulins: pathophysiology in immunologic infertility and local immune defense.
Mutation in the protease cleavage site of GDF9 increases ovulation rate and litter size in heterozygous ewes and causes infertility in homozygous ewes.
Infertility, Male
Association between ubiquitin-specific protease USP26 polymorphism and male infertility in Chinese men.
Association of 370-371insACA, 494T>C, and 1423C>T haplotype in ubiquitin-specific protease 26 gene and male infertility: a meta-analysis.
Immune mediators associated to male infertility in a mouse model of DNA immunization with the sperm protease proacrosin.
Novel mutations in testis-specific ubiquitin protease 26 gene may cause male infertility and hypogonadism.
Novel mutations in ubiquitin-specific protease 26 gene might cause spermatogenesis impairment and male infertility.
Ubiquitin-specific protease (USP26) gene alterations associated with male infertility and recurrent pregnancy loss (RPL) in Iranian infertile patients.
Ubiquitin-specific protease activity of USP9Y, a male infertility gene on the Y chromosome.
Inflammatory Bowel Diseases
A low dose of fermented soy germ alleviates gut barrier injury, hyperalgesia and faecal protease activity in a rat model of inflammatory bowel disease.
Association between single nucleotide polymorphisms in prospective genes and susceptibility to ankylosing spondylitis and inflammatory bowel disease in a single centre in Turkey.
ERAP1 and HLA-C interaction in inflammatory bowel disease in the Spanish population.
Genetic evidence supporting the association of protease and protease inhibitor genes with inflammatory bowel disease: a systematic review.
Genetic markers and inflammatory bowel disease: immunoglobulin allotypes (GM, KM) and protease inhibitor.
Genome-wide association analysis identifies new susceptibility loci for Behet's disease and epistasis between HLA-B*51 and ERAP1.
Protease inhibitors in plasma and faecal extracts from patients with active inflammatory bowel disease.
Protease inhibitors on trial for inflammatory bowel disease.
Influenza in Birds
Hemagglutinin activation of pathogenic avian influenza viruses of serotype H7 requires the protease recognition motif R-X-K/R-R.
Protease activation mutants elicit protective immunity against highly pathogenic avian influenza viruses of subtype H7 in chickens and mice.
Replication of a low-pathogenic avian influenza virus is enhanced by chicken ubiquitin-specific protease 18.
The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine.
Influenza, Human
Allantoic fluid protease activity during influenza virus infection.
Approach to the involvement of influenza B neuraminidase in the cleavage of HA by host cell protease using low pH-induced cell fusion reaction.
Aprotinin and similar protease inhibitors as drugs against influenza.
Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus.
Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors.
Human mucus protease inhibitor in airway fluids is a potential defensive compound against infection with influenza A and Sendai viruses.
Identification of trypsin I as a candidate for influenza A virus and Sendai virus envelope glycoprotein processing protease in rat brain.
Inhibition of influenza virus infection and hemagglutinin cleavage by the protease inhibitor HAI-2.
Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2.
Inhibition of the protease activity of influenza virus RNA polymerase PA subunit by viral matrix protein.
Inhibitory effect of a protease inhibitor, leupeptin, on the development of influenza pneumonia, mediated by concomitant bacteria.
MicroRNA regulation of human protease genes essential for influenza virus replication.
Modulation of airway smooth muscle tone by protease activated receptor-1,-2,-3 and -4 in trachea isolated from influenza A virus-infected mice.
Molecular mechanism of complex infection by bacteria and virus analyzed by a model using serratial protease and influenza virus in mice.
p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1.
Potentiation of infectivity and pathogenesis of influenza A virus by a house dust mite protease.
Protease susceptibility of human A influenza virus polypeptides.
Protective effect of protease inhibitors in influenza virus infected animals.
Role of Staphylococcus protease in the development of influenza pneumonia.
Sialidase and protease activities of commercial (RDE) receptor destroying enzyme products used for the (HI) hemagglutination inhibition test of influenza viruses]
Suppression of influenza virus replication in infected mice by protease inhibitors.
The action of protease on influenza A2 virus.
The effect of protease treatment on the morphology of influenza A, B and C viruses.
The host protease TMPRSS2 plays a major role for in vivo replication of emerging H7N9 and seasonal influenza viruses.
The human mucus protease inhibitor and its mutants are novel defensive compounds against infection with influenza A and Sendai viruses.
The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes.
Trypsin-resistant protease activation mutants of an influenza virus.
[Changes in the protease activity in the lungs of mice infected with the influenza A virus]
[Effect of protease inhibitors on influenza virus reproduction]
[Effect of protease inhibitors on the course of experimental influenza]
[Influenza A virus M1 matrix protein is similar to protease inhibitors]
[Participation of the proteolysis system in promoting the virulence of the influenza virus and development of the infectious process; the antiviral effect of protease inhibitors]
[Protease inhibitor suppression of influenza virus replication in the lungs of infected mice]
[Protease inhibitors block the spread of the influenza virus in the body of infected animals]
Insulin Resistance
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors.
Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors.
Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance.
Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.
Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.
Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s.
Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial.
Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy.
Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.
HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models.
Human obesity and thinness, hyperlipidemia, hyperglycemia, and insulin resistance associated with HIV1 protease inhibitors. Prevention by alternating several antiproteases in short sequences.
Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.
Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.
Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir.
In vitro and in vivo prevention of HIV protease inhibitor-induced insulin resistance by a novel small molecule insulin receptor activator.
Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution.
Insulin resistance complicating pregnancy in a human immunodeficiency virus-infected patient treated with protease inhibitors and corticosteroids.
Insulin resistance in HIV protease inhibitor-associated diabetes.
Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children.
Loss of mitochondrial protease ClpP protects mice from diet-induced obesity and insulin resistance.
Macrophage ubiquitin-specific protease 2 modifies insulin sensitivity in obese mice.
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-infected patients.
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.
The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes.
The mechanism of insulin resistance caused by HIV protease inhibitor therapy.
The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.
Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.
[The HIV protease inhibitor-induced insulin resistance syndrome]
Insulinoma
[Effects of various HIV protease inhibitors on function of rat insulinoma cells]
Intellectual Disability
Enzymatic properties and localization of motopsin (PRSS12), a protease whose absence causes mental retardation.
Specific cleavage of agrin by neurotrypsin, a synaptic protease linked to mental retardation.
Intervertebral Disc Degeneration
Chondroadherin fragmentation mediated by the protease HTRA1 distinguishes human intervertebral disc degeneration from normal aging.
Intracranial Hemorrhages
[Protease inhibitors in the treatment of intracranial hemorrhage]
Intracranial Thrombosis
Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis.
Irritable Bowel Syndrome
Altered protease signalling in the gut: a novel pathophysiological factor in irritable bowel syndrome.
Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit.
Protease activated receptor 4 status of mast cells in post infectious irritable bowel syndrome.
Protease Activated Receptor-2 Induces Immune Activation and Visceral Hypersensitivity in Post-infectious Irritable Bowel Syndrome Mice.
Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients.
Role for protease activity in visceral pain in irritable bowel syndrome.
Ischemic Attack, Transient
Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia.
Joint Diseases
[Protease inhibitors of the synovial fluid in the pathogenesis and diagnosis of joint diseases]
[Role of protease inhibitors in therapy of joint diseases]
[The effectiveness of the protease inhibitor Contrykal in the drug therapy of arthrosis deformans]
[The treatment of joint diseases with the protease inhibitor Contrykal]
Keratitis
Characterization of rabbit corneal damage produced by Serratia keratitis and by a serratia protease.
Pseudomonas aeruginosa MucD protease mediates keratitis by inhibiting neutrophil recruitment and promoting bacterial survival.
Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence.
Role of contact lens wear, bacterial flora, and mannose-induced pathogenic protease in the pathogenesis of amoebic keratitis.
The serratial 56K protease as a major pathogenic factor in serratial keratitis. Clinical and experimental study.
Keratoconjunctivitis Sicca
Association of HLA-DR4, protease inhibitor phenotypes and keratoconjunctivitis sicca with pulmonary abnormalities in rheumatoid arthritis.
Keratoconus
Effects of eye rubbing on the levels of protease, protease activity and cytokines in tears: relevance in keratoconus.
Expression of degradative enzymes and protease inhibitors in corneas with keratoconus.
Normal expression levels of cathepsins, protease inhibitors, and Sp1 in conjunctival tissues from patients with keratoconus.
Keratoderma, Palmoplantar
Nagashima-type palmoplantar keratosis: a common Asian type caused by SERPINB7 protease inhibitor deficiency.
Ketosis
Ketoacidosis associated with protease inhibitor therapy.
Kidney Diseases
NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor.
The Multifaceted Role of the Lysosomal Protease Cathepsins in Kidney Disease.
Kidney Failure, Chronic
Alteration in insulin-like growth factor-binding proteins (IGFBPs) and IGFBP-3 protease activity in serum and urine from acute and chronic renal failure.
Fibrinolytic and protease inhibitory systems in spinal cord injured patients with end-stage renal disease.
HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance: Which Salvage Regimen?
Increased plasma glycosidase and protease activity in uraemia: possible role in the aetiology of the anaemia of chronic renal failure.
Insulin-like growth factor binding protein-3 protease activity in the urine of children with chronic renal failure.
Leg Ulcer
A 'test and treat' strategy for elevated wound protease activity for healing in venous leg ulcers.
Cytokine and protease levels in healing and non-healing chronic venous leg ulcers.
Protease activity as a prognostic factor for wound healing in venous leg ulcers.
Quantification of secretory leucocyte protease inhibitor in exudates from leg ulcers of patients with diabetes.
Legionnaires' Disease
Immunocytochemical demonstration of the association between Legionella pneumophila, its tissue-destructive protease, and pulmonary lesions in experimental legionnaires' disease.
Separation of Legionella pneumophila proteases and purification of a protease which produces lesions like those of Legionnaires' disease in guinea pig lung.
Leiomyoma
Protease activity in fibromyoma and normal human myometrium.
Relaxin increases elastase activity and protease inhibitors in smooth muscle cells from the myometrium compared with cells from leiomyomas.
Leishmaniasis
Protease inhibitors as prophylaxis against leishmaniasis: new hope from the major surface protease gp63.
Protease inhibitors in potential drug development for Leishmaniasis.
Leishmaniasis, Visceral
Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy.
Leprosy, Lepromatous
Protease inhibitors activity in lepromatous leprosy and lepra reaction.
Leukemia
28-kDa mammalian heat shock protein, a novel substrate of a growth regulatory protease involved in differentiation of human leukemia cells.
A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation.
Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture.
Avian sarcoma leukemia virus protease linked to the adjacent Gag polyprotein is enzymatically active.
Blockade of the Ubiquitin Protease UBP43 Destabilizes the Transcription Factor PML/RAR{alpha} and Inhibits Growth of Acute Promyelocytic Leukemia.
Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases.
Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis.
DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies.
Extracellular protease trypsin activates amiloride-insensitive sodium channels in human leukemia cells.
Identification and cloning of a novel isoform of mouse secretory leukocyte protease inhibitor, mSLPI-beta, overexpressed in murine leukemias and a highly liver metastatic tumor, IMC-HA1 cells.
Insulin-like growth factor bi